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MECHANISMS OF ASTROCYTE CONTRIBUTION TO BORTEZOMIB-INDUCED
PERIPHERAL NEUROPATHY

Caleb Robert Robinson, B.S.
Advisory Professor: Patrick M. Dougherty, Ph.D.

Bortezomib is a proteasome inhibitor used in the treatment of multiple
myeloma and other non-solid malignancies, alone or in combination with other
chemotherapy drugs. Like other chemotherapeutic agents, bortezomib treatment is
frequently accompanied by chemotherapy-induced peripheral neuropathy (CIPN)
that may be dose-limiting, adversely affecting quality of life and prognosis. The
mechanisms behind bortezomib-induced peripheral neuropathy (BIPN) and CIPN
overall are largely unknown. Recent findings in other pain models have indicated
substantial involvement of glial cells in chronic pain. Although injury models have
shown activation of both astrocytes and microglia following insult, research in other
CIPN models has shown astrocytic activation in the absence of microglial activation.
The central hypothesis of this dissertation is that the activity of astrocytes is
correlated with behavioral changes observed in a rat model of BIPN in a manner that
may directly contribute to these changes in behavior. To investigate this, the work of
this dissertation 1) established the multimodal changes to behavior and showed
increases in spinal neuron firing in BIPN, 2) quantified activity of astrocytes and
whether changes were prevented by minocycline, an anti-inflammatory drug that
v

prevents glial activation, and 3) quantified changes in connexin 43, GLT-1, and
GLAST to assess whether astrocytic glutamate transport may be altered in BIPN.
The results observed in the first aim were that the rat BIPN model is characterized
by selective mechanical hypersensitivity and a significant increase in wide dynamic
range (WDR) neuron firing rates and after-discharges. In the second aim, astrocytes
in the BIPN model were activated in a manner that paralleled the behavioral
changes. Animals co-treated with minocycline resembled saline-treated animals in
both astrocytic activation and behaviors. The results in the third aim were that
astrocytic gap junctions were increased and GLAST expression was decreased at
the height of mechanical sensitivity. Minocycline-treated animals resembled salinetreated animals in expression of these proteins, as well. The overall conclusion was
that astrocyte activity closely paralleled behaviors in the BIPN model in a manner
that may be explained by their role in glutamate trafficking.
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1.

GENERAL INTRODUCTION

1.1.

Neuropathic Pain
Chronic pain is a widespread and significant problem with regard to quality of

life, medical care costs, and loss of productivity at work. Neuropathic pain is a
phenomenon distinct from other forms of pain in that it is caused by damage or insult
directly to the nerves or CNS, often without inflammation or damage to the
surrounding tissue (Jay and Barkin, 2014). Instead, neuropathic pain is a condition
that develops independently within nerves or lingers after tissue damage has
recovered due to damage, toxicity, or other insult directly to a part of the
somatosensory tract (Treede et al., 2008, Baron, Binder, and Wasner, 2010). The
pain may be classified as spontaneous pain in the absence of an identifiable
stimulus, increased sensitivity to painful stimuli (hyperalgesia), or painful sensations
to otherwise non-noxious stimuli (allodynia) (Costigan, Scholz, and Woolf 2009; Jay
and Barkin, 2014). Furthermore, neuropathic pain is not limited to one modality, but
may include altered sensitivity to thermal (heat or cold) and mechanical stimuli
(Baron, Binder, and Wasner, 2010). Changes in sensitivity to stimuli may also take
the form of spontaneous numbness, tingling, burning, or shooting sensations that
occur as a result of maladaptive persistent firing in affected neurons (Freynhagen
and Bennett, 2009; Baron, Binder, and Wasner, 2010). Neuropathies may include
altered sensory symptoms alone, although individuals with neuropathy may also
show a degree of fine or gross motor ability impairment that may interfere with daily
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living (Casellini and Vinik, 2007). However, this profile may vary depending on the
type of neuropathic pain, and not all forms of sensory neuropathy also exhibit motor
neuropathy. This in itself is sufficient to suggest that neuropathic pain should be
treated as a class of distinct conditions that may present similar symptoms through
the differing mechanisms.
Among various classes of neuropathies that may present with sensory
symptoms are injury-induced neuropathy, diabetic neuropathy, alcoholic neuropathy,
and chemotherapy-induced peripheral neuropathy (CIPN) (Gregory et al., 2013),
although this list is not exhaustive. Injury-induced neuropathies may be induced via
damage to peripheral sites, such as the primary afferent nerve or dorsal root
ganglion, or central sites, such as the spinal cord. Whereas the first category
presents with deficits localized to the dermatome associated with the injury, damage
directly to the spinothalamic tracts in the spinal cord produces deficits starting at a
level of the body and extending downward (D’Angelo et al., 2013). Systemic
neuropathies may affect multiple regions of the body, but a ―stocking and glove‖
distribution (hands and feet) is most common (Brix Finnerup, Hein Sindrup, and
Staehelin Jensen, 2013). The reason behind this is not fully clear, but it could be that
peripheral nerve lengths or nerve fiber densities within the skin are linked to the
distribution of neuropathy. Longer nerves would be more sensitive to demyelination,
axonal degradation, or changes to conduction velocity that could drive maladaptive
or persistent signaling. Alternatively, dying back of intra-epidermal nerve fibers
(IENFs) in skin could result in initial painful sensations at moderate levels of
denervation, with numbness occurring as the region approaches complete
2

denervation. If there is a release of neuropeptides or other signaling molecules that
could explain sensitization of neurons, then the recruitment of a greater cohort of
nerve endings could produce a more pronounced response of this kind. Since the
stocking-and-glove regions of the body possess relatively lower number of free
nerve endings when compared with other regions of the extremities in healthy
control subjects (Boyette-Davis et al., 2011b; Mancini et al., 2013), these would then
be most susceptible. Indeed, not only has IENF loss been linked to multiple types of
neuropathy, but the loss of IENFs has been reported to be most pronounced in
those areas with the most pronounced painful symptoms (Petersen et al., 2000;
Boyette-Davis et al., 2011b; Jay and Barkin, 2014). However, the reason for the
stocking-and-glove distribution may vary based on the mechanisms driving the
specific type of neuropathy, and evidence is still lacking to determine a cause.
Treatment options for neuropathies that present with painful symptoms are
limited. Because the various causes of neuropathy are not well understood and may
not act through a single common pathway, the best option currently available is
simply to treat the pain symptoms, rather than to address the cause. There are
currently a multitude of drugs that are being investigated for this purpose, including
gabapentin, pregabalin, tricyclic antidepressants, and serotonin-norepinephrine
reuptake inhibitors, but the most effective treatment option is chronic administration
of strong opioids (Attal, 2012). However, this option comes with the obvious
possibility of tolerance, addiction, or abuse, and there is a clear need for a better
solution. Furthermore, there is emerging evidence that chronic opioid treatment may
result in the development of opioid-induced hyperalgesia that could worsen
3

neuropathic pain sensation in the long run (Brush, 2012). It is therefore critical to try
to identify methods for reversing or preventing neuropathy, whatever the cause may
be. Unfortunately, injury-based neuropathies cannot be predicted, and preventative
treatment is thus impossible. While diabetes and alcoholism are risk factors for the
development of neuropathic pain, these conditions also do not provide a means for
pinpointing the onset of neuropathy. At best, diabetic and alcoholic neuropathy can
be identified early on, and attempts may be made to curtail worsening symptoms.
However, chemotherapy-induced peripheral neuropathy is unique among
neuropathies in that the insult that induces neuropathy is scheduled by appointment.
It is therefore a promising system for studying neuropathic pain as a whole and for
developing methods for its prevention and reversal. It is not currently known if there
are common mechanisms that govern CIPN and other forms of peripheral
neuropathy, but the prospect of finding treatments in CIPN that may translate to
other forms of neuropathy and chronic pain certainly warrants further study.

1.2.

Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy is a treatment-emergent side

effect of regular chemotherapy treatment with paresthesias and neuropathic pain as
the most common symptoms (Argyriou et al. 2014). While this form of neuropathy
may also impact motor ability or autonomic function, these side effects are limited to
certain drugs and generally emerge as sensory symptoms worsen. The severity of
the neuropathy varies by patient and by total cumulative dose, but may emerge after
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as little as a single cycle of treatment (Argyriou, Iconomou, and Kalofonos, 2008;
Tofthagen, McAllister, and McMillan, 2011; Boyette-Davis et al., 2012). Usually the
course of the neuropathy is simply monitored at Grade 1 peripheral neuropathy (mild
paresthesias/partial loss of deep tendon reflexes), but progression to Grade 2
peripheral neuropathy (severe paresthesias/absent deep tendon reflexes with mild
impairment of daily activity) frequently results in dose reduction, and progression to
Grade 3 (disabling sensory loss/paresthesias that severely impair normal activity) or
Grade 4 (permanent loss of sensory function or paralysis) peripheral neuropathy
often necessitates termination of treatment altogether (Postma and Heimans, 2000;
Miltenburg and Boogerd, 2014). Painful symptoms may also necessitate the
termination of treatment if symptoms do not respond to conventional treatments.
CIPN is therefore a concern for not only quality of life in patients receiving
chemotherapy treatment, but is also a concern with regard to patient survival
outcomes when patients must reduce treatment to levels below effective doses to
treat cancer or cease treatment altogether.
Most studies regarding the clinical presentation of CIPN focus on patientreported sensations in order to evaluate symptoms and severity. Although these
measures are easy and convenient to obtain, they may vary widely from one patient
to another, especially with regard to an individual’s sensitivity to pain or biases in
reporting. The development of quantitiative sensory testing measures has been
instrumental in implementing objective measures for the evaluation of patient CIPN,
and work has been carried out to characterize this in vincristine, taxol, and
bortezomib-induced peripheral neuropathy at this time (Cata et al., 2007; Dougherty
5

et al., 2007; Boyette-Davis et al., 2011a; Boyette-Davis et al., 2013). The findings of
these studies (summarized in Table 1) have demonstrated a trend in loss of
sensation within affected areas across all of these drugs. This suggests the
possibility of a central governing mechanism behind CIPN, although this cannot yet
be verified. Furthermore, these studies provide a means by which preclinical
experiments may be checked against the clinical presentation, as analogous
behavioral measures exist within animal models for most of the same affected
modalities. This may further help in translational studies moving forward to identify
how preventative treatments identified in animals affect patients and whether
patients show objective improvement in symptoms.

Vincristine
Numbness, tingling,
Most common
throbbing, burning,
Descriptors
sharp

Paclitaxel

Bortezomib

Numbness, tingling,
burning

Numbness, tingling,
burning

Affected
regions

Hands and feet,
primarily in fingers
and toes

Hands and feet,
primarily in fingers
and toes

Hands and feet,
primarily in fingers
and toes, more
severe in lower
extremities

Affected
modalities

Crude touch, sharp
touch, thermal, fine
motor

Crude touch, sharp
touch, thermal, fine
motor

Crude touch, sharp
touch, thermal, cold,
fine motor

Table 1. Quantitative sensory testing (QST) and patient-reported symptoms in
patients treated with vincristine, paclitaxel, or bortezomib
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1.3.

Rat Models of Neuropathy
Neuropathic pain can be modeled in rats in a number of ways, but the most

common of these is through direct injury to the spinal cord or peripheral nerve
through surgical means. The spinal cord may be directly injured via contusion from
the drop of a small weight (Gruner, 1992) or by surgical section or hemisection
(Vierck, Hamilton, and Thornby, 1971; Levitt and Levitt, 1981; Christensen et al.,
1996). Alternative means of spinal cord injury may include laser irradiation to induce
ischemic injury (Hao et al., 1991) or microinjection of quisqualic acid to induce
excitotoxicity (Yezierski et al., 1993). These models produce spontaneous behaviors
interpreted as painful and evoked mechanical and thermal hyperalgesia, but
targeting the spinal cord is less precise than targeting a peripheral nerve, which
allows localization to a single dermatome and is less likely to induce unwanted motor
deficits. Injury models at the peripheral nerve are also simpler procedures and less
invasive, usually being based on tying a ligature around some point of the nerve.
These differ mostly in their location, with spinal nerve transection (SNT) and spinal
nerve ligation (SNL) at the segmental nerve root of one or more nerves composing
the sciatic nerve (Ringkamp et al., 1999; Kim and Chung, 1992), chonic constriction
injury and partial nerve transection at the common sciatic nerve (Bennett and Xie,
1988; Seltzer, Dubner, and Shir, 1990), and spared nerve injury (SNI) targeting two
branches of the sciatic nerve (Decosterd and Woolf, 2000). Like the models that
target the spinal cord directly, these injury models also produce robust mechanical
and thermal hyperalgesia.
7

Alcoholic neuropathy is usually modeled either through replacement of water
with an ethanol solution (Juntunen et al., 1978) or through chronic administration of
ethanol via oral gavage, which is beneficial for standardizing alcohol consumption
between animals (Kandhare et al., 2012). Diabetic neuropathy may be modeled
through genetic knockout mice (including, but not limited to knockouts for insulin 1
(Ins.Dd1) or insulin 2 (C57BL/6-Ins2Akita/J) expression) or through injection of
streptozotocin, although which genes are targeted and what dose of streptozotocin
is used may vary distinctly from one study to another (Sullivan et al., 2008). These
neuropathies may be characterized by hyper- or hypoalgesia with regard to
mechanical and/or thermal stimuli, once again varying by drug dose and genetic
knockout. Chemotherapy-induced peripheral neuropathy is modeled by systemic
injection of chemotherapeutic agents on schedules that may vary from one protocol
to another. Affected modalities vary based on drug and are discussed in more detail
later.
One drawback of modeling neuropathic pain in animals is the lack of
distinction between painful sensations and non-painful sensations (e.g. tingling)
when using the reflex measures commonly employed in these models. Whereas
other types of pain (such as inflammatory pain) are not accompanied by these types
of paresthesias, direct insults to the nerve commonly produce numbness and tingling
in humans (Kim and Kim, 2012; Lau and Stavrou, 2004). It is therefore possible in
any of these animal models that hyper-reflexive responses may occur in response to
such sensations. However, there is currently no commonly-used method to
distinguish between these sensations in animal models. This is a concern that
8

should be considered in the design of any experiment, and care must be taken to
ensure that interpretations of observations are not dependent on the animal feeling
pain instead of some form of non-painful paresthesia.

1.4.

The Proteasome and Its Inhibition by Bortezomib
Among the many drugs that may induce chemotherapy-induced peripheral

neuropathy is bortezomib, a drug that targets the activity of the proteasome. It is
unclear at this time whether bortezomib may have additional targets, but it was
developed for its action with regard to the proteasome. The 26S proteasome is the
major proteolytic structure in the majority of human somatic cells, consisting of two
19S regulatory subunits and a 20S subunit that is capable of degrading any
misfolded, obsolete, or otherwise unnecessary proteins within the cell
(Bhattacharyya et al., 2014). The 19S subunit of the proteasome detects polyubiquitylated tails that are attached to these proteins through the activity of ubiquitin
ligases, then passes them into the pore of the tube-shaped 20S subunit. This 20S
subunit can degrade proteins into constituent amino acids through trypsin-like,
chymotrypsin-like, or peptidyl-glutamyl-peptide bond hydrolyzing activity, based on
which active site the ubiquitylated protein is capable of binding (Schreiber and Peter,
2014). Because these sites are located on the interior of the 20S subunit pore, only
proteins recognized by the 19S subunit come into contact with them. Once the
protein is digested by the activity of these catalytic sites, the constituent amino acids
are then available for protein synthesis within the cell once more.

9

In addition to maintaining functionality of the cell by degrading inappropriate
proteins, the proteasome is also important for maintaining the balance of proteins
related to regular cell function. Progression of the cell cycle requires the activity of
the proteasome to degrade certain proteins that keep the cell in its current growth
phase. For example, the anaphase promoting complex (APC), a type of ubiquitin
ligase, is responsible for ubiquitylating a host of substrates that appear to be
necessary for anaphase to occur during cell division (Merbl and Kirschner, 2009). It
is not fully understood which of these substrates are necessary for mitosis to
proceed, as the substrates of the APC include a diverse array of cellular proteins.
However, the necessity of a ubiquitin ligase in the progression of the cell cycle is
also sufficient to implicate the proteasome as necessary for it to occur. This may not
be a contributing factor in the context of CIPN, but is thought to be one possible
mechanism for bortezomib’s anti-tumor activity. The APC is not the only ubiquitin
ligase involved in the cell cycle, but many types of E1, E2, and E3 ubiquitin ligases
are needed in order for the cell cycle to progress, with only a handful that have been
identified at this time in tumor progression out of several hundred ubiquitin ligases
(Mattern, Wu, and Nicholson, 2012). The proteasome is therefore vital in all of these
cases, governing many stages in the life of a cell and serving as a common ground
to target a multitude of diverse and poorly-understood mechanisms simultaneously.
It is based largely on this role in driving the cell cycle that the proteasome was
identified as a target for chemotherapy, and this is one of the means by which
bortezomib is thought to affect tumor progression. Most somatic cells in adults do
not require frequent cell cycle turnover, but cancer cells are highly proliferative.
10

However, the developers of bortezomib also recognized several other means by
which it may act to sensitize or kill cancer cells. Bortezomib may have a greater
effect on cancer cells in part simply because of the very high metabolic demand in
malignant tissue. In support of this, bortezomib has been shown to inhibit
angiogenesis by downregulating associated genes (e.g. VEGF and IL-6), stunting
tumor growth and progression (Roccaro et al., 2006). Another possible explanation
for bortezomib’s activity is through the accumulation of the tumor suppression
protein p53. Upregulation of this protein in response to potentially tumorigenic
mutations results in apoptosis, and successfully proliferating tumors continually
ubiquitylate p53 in order to prevent this from occurring (Melvin et al., 2013). The
inhibition of the proteasome therefore may result in the accumulation of p53 and
subsequent apoptosis of cancer cells. Inhibition of the proteasome also stabilizes
IκB, the inhibited form of NF-κB, which must normally be degraded before NF-κB
can become active (Richardson, Hideshima, and Anderson, 2003). The activity of
this transcription factor is diverse, but it promotes the expression of inhibitors of
apoptosis such as Bcl-2, XIAP, and suvivin and downregulates pro-apoptotic
signaling from Bax (Mitsiades et al., 2002). NF-κB is constitutively upregulated in
multiple myeloma cells to promote tumor survival in a manner that was prevented by
bortezomib (Berenson, Ma, and Vescio, 2001; Ma et al., 2003). Endoplasmic
reticulum-mediated apoptosis is another possible mechanism by which bortezomib
may trigger cell death in malignant cells. While the ER may be affected by Bcl-2
signaling and therefore be tied to NF-κB regulation, it may also trigger apoptosis on
its own. Accumulation of misfolded proteins at low levels triggers a pro-survival
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response in the endoplasmic reticulum of cells, but when this progresses beyond a
point that is manageable, the ER then triggers a pro-apoptotic signal cascade via
increases in intracellular calcium (Ferri and Kroemer, 2001; Landowski et al., 2005).
It seems unlikely that any one of these possibilities is the sole answer for how
bortezomib acts as a chemotherapy drug. Instead, a combination of these
mechanisms may work in tandem in order to induce cancer cell apoptosis or slow
metastasis of the malignancy.
Bortezomib was one of several proteasome inhibitors developed with the
intent of chemotherapeutic use, but it was the first to gain FDA approval for use in
cancer treatment (Cavo 2006). Bortezomib targets the chymotrypsin-like activity of
the 20S proteasome subunit and binds competitively to this site (Lightcap et al.,
2000; Cavo 2006). It has a half-life lasting 24 hours, and proteasomal activity returns
to basal levels between 72 and 96 hours following administration of bortezomib
(Adams 2001). Bortezomib cannot cross the blood brain barrier and does not
penetrate into the brain, spinal cord, testes, or eyes (Adams et al., 1999; Adams
2001).Bortezomib is usually administered at 1.3mg/m² or 1.0mg/m² either
intravenously or subcutaneously (with equal efficacy) in cycles of 4 doses over 2
weeks, followed by a week without treatment (Arnulf et al.,2012; Zeng, Lin, and
Chen, 2013). Number of cycles may then vary. Bortezomib has been proven
effective in patients who are refractory and no longer responding to other forms of
treatment (Richardson et al., 2003). It may be given alone in non-solid malignancies
such as multiple myeloma, and single-agent treatment of bortezomib has resulted in
partial responses or better in 41% of patients (Richardson et al., 2009). However, it
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is also effective in increasing positive responses when used in combination with
other chemotherapy drugs such as thalidomide, dexamethasone, melphalan, or
prednisone (San Miguel et al., 2008; Jagganath et al., 2009; Cavo et al., 2010;
Mateos et al., 2010; Arnulf et al.,2012; Zeng, Lin, and Chen, 2013). These studies
have demonstrated that response rates are greater when bortezomib is employed
alongside these drugs, but the incidence and severity of adverse events also
increases. The most common side effects observed in bortezomib treatment include
chemotherapy-induced peripheral neuropathy, neutropenia, thrombocytopenia,
anemia, and diarrhea (Reece et al., 2006).

1.5.

Clinical Presentation of Bortezomib-Induced Peripheral Neuropathy
Bortezomib-induced peripheral neuropathy follows closely with the

aforementioned trend of CIPN as a whole in patients: a stocking and glove
distribution, poor response to pain medication, and symptoms that may necessitate
reduction or cessation of treatment. However, BIPN does vary somewhat in how it
presents in patients versus other forms of CIPN. Total incidence of BIPN was 35% of
patients in the CREST and SUMMIT trials, with 12% of patients experiencing grade
3 or higher peripheral neuropathy (Jagannath et al., 2006). Another study reported
BIPN in 40% of treated patients, with 15% of patients experiencing grade 3 or higher
peripheral neuropathy (Bang et al., 2006). This was the second most common
adverse event in this study, with thrombocytopenia reported at 45% of patients (38%
in the first study). However, while the thrombocytopenia was transient in both
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studies, returning to near-baseline levels at the end of each cycle, sensory
neuropathy induced by bortezomib lingers after cessation of treatment. Some
studies report a higher incidence of peripheral neuropathy, but this may be in part
due to pre-existing levels of peripheral neuropathy from other forms of treatment that
predispose patients to worsening treatment-emergent neuropathy (Richardson et al.,
2009). The intensity of BIPN is very pronounced, even in the presence of daily pain
medication, with patients reporting daily maximum pain at a mean rating of 7.8 out of
10 (Cata et al., 2007). However, incidence of painful peripheral neuropathy is
generally not noted separately from that of peripheral neuropathy presenting with
sensory loss or paresthesias. Regardless, dose modification guidelines do seem to
have a positive impact on management peripheral neuropathy symptoms, and
patients with BIPN have been reported as experiencing improvement or recovery
from sensory neuropathy at a median time of 110 days (Richardson et al., 2009).
Of the studies conducted in human subjects with BIPN, few have been
published relating to mechanistic studies or preventative treatment strategies. Many
of these have focused on the identification of genetic factors associated with BIPN.
Targets of interest to follow up on in these studies include altered expression of
genes related to general immune function, TNFα, caspases, and general
mitochondrial function (Broyl et al., 2010; Favis et al., 2011; Corthals et al., 2011).
However, since samples were obtained from patient blood samples, it cannot be
said for sure whether these changes would also be observed in nervous tissue,
especially since the blood is taken from individuals treated for a hematologic
malignancy. Nevertheless, these are potential targets for future research. Apart from
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genetic studies, investigators have identified potential contributing factors to BIPN,
including increased axonal depolarization prior to full onset and reduced levels of
soluble BDNF in blood (Nasu et al., 2014; Azoulay et al., 2014), but these findings
have not yet been validated.
Comparatively little is known about BIPN in patients for several reasons. First
of all, the drug has only been on the market for about 10 years. Taken together with
the fact that it is the first proteasome inhibitor approved for use in the treatment of
cancer, there has been less time for research into the causes and effective
treatment of BIPN versus the CIPN induced by other drugs. Second, the survival
times for multiple myeloma patients are poor, even with bortezomib treatment. This
makes it difficult for investigators to follow up on long-term effects and recovery in
clinical trials. Furthermore, there is still little to no standardization of the evaluation of
CIPN as a whole. Whereas the bulk of studies and clinical assessments rely on
patient-reported symptoms and questionnaires that may be biased, a mere handful
of researchers have attempted objective quantifications in BIPN (Richardson et al.,
2006; Cata et al., 2007; Boyette-Davis et al., 2011a). Apart from these studies, there
is little reliability in identifying and assessing the severity of BIPN from one patient to
the next. Preclinical animal studies in a BIPN model would be an attractive means of
studying BIPN not only because of the greater potential for controlled mechanistic
studies, but also because of widely-implemented objective behavioral measures that
allow for reliability in replicating and following up on findings from other studies.

15

1.6.

Current Findings in Animal Models of Bortezomib-Induced Peripheral

Neuropathy
Animal studies in BIPN have been relatively few when compared against
other classes of chemotherapy drugs. Part of this is no doubt due to the relative
novelty of proteasome inhibitors as chemotherapeutic agents. The single most
prolific contributor to what research currently exists is the Cavaletti lab. The first
major study in animals by this group did not include any behavioral measures, but
reported decreases in tail nerve conduction velocity and damage to Schwann cells
and DRG (Cavaletti et al., 2007). However, the doses used in this study were much
higher than those given to patients. It is therefore uncertain how much of the
reported damage is directly linked to BIPN and how much may be due to excessive
toxicity. Furthermore, a follow-up study examining the myelin within these Schwann
cells found that bortezomib produced no difference in myelination and a great deal of
variability between individuals (Gilardini et al., 2012). This should also call into
question whether or not the purported axonopathy and changes to nerve conduction
velocity are valid. A recent paper published by the Cavaletti lab demonstrated
increased mechanical sensitivity and firing rates of WDR neurons in the absence of
changes in response to thermal or cold stimuli (Carozzi et al., 2013). This study also
claimed to demonstrate changes in nerve conduction velocity and axonal
degeneration, but the changes observed were not robust in the former and were
completely absent of any quantification in the latter. Nevertheless, the other findings
are in agreement with what has been found in our own lab in a rat model. Another
recent study from this lab has investigated potential molecular changes in the
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bortezomib model in spinal cord and dorsal root ganglia (Quartu et al., 2014). The
study showed increases in levels of TRPV1, CGRP, and substance P, but there
were several concerns present within the data. First, this study included only a single
behavioral time point apart from baseline which showed an elevation of threshold in
control animals, rather than an increase in sensitivity in bortezomib-treated animals.
The difference between the two groups was modest, at best, and adding additional
time points may have abolished this effect. There was also a reciprocal downregulation of mRNA expression for proteins that showed greater expression in other
measures that was explained as a possible effect of the proteasome. It is unclear
whether or not this would be the case without further study. Also, representative
Western blots showed inconsistency in GADPH control bands, as well as several
GADPH bands which clearly came from different blots than the accompanying bands
for TRPV1. RT-PCR had similar issues. Finally, the quantification of
immunohistochemistry showed modest changes with overlapping error bars in every
case, making the claims of significance using t-tests possible, but suspicious. This
should not suggest that the changes observed do not occur, but that the major
issues within the data necessitate follow-up research to verify the findings of this
study.
An earlier study from Bennett’s lab using rats differs in its results from
Cavaletti’s work in that no axonal degradation was observed, but cold hyperalgesia
was reported (Zheng, Xiao, and Bennett, 2012). This study also reported mitotoxicity
in primary afferents and used this as the proposed mechanism driving BIPN.
However, patients often report neuropathic pain symptoms in BIPN without any
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muscular weakness, and other mitochondria-dense regions such as the eyes are
unaffected. Another group has reported cold sensitivity after a single dose of
bortezomib treatment, as well as a prevention of both mechanical and cold
sensitization in TRPA1 knockout mice (Trevisan et al., 2013). However, the paper
also reported that bortezomib does not directly activate or alter expression of TRPA1
receptors, and how mechanosensation would be affected by a TRPA1 knockout is
unclear.
Surprisingly, only a few preventative treatments have been investigated for
the treatment of BIPN in animals. However, one study of interest identified TNF-α
and IL-6 as potential therapeutic targets within the dorsal root ganglion (Alé et al.,
2014). Levels of TNF-α and IL-6 were reported to be higher in the DRG of
bortezomib-treated animals than controls, and antibodies against these were
successful in preventing the development of a change in behavior and preventing
their upregulation. This finding provides evidence in support of a mounting theory in
neuropathy as a whole, that proinflammatory signals are necessary and possibly
even sufficient to drive peripheral neuropathy. Furthermore, a signal cascade
beginning with a proinflammatory signal in the dorsal root ganglion could be
sufficient to induce changes observed in the spinal cord, as it has been established
that bortezomib cannot cross the blood-brain barrier (for further discussion, see
Conclusion). However, the fact remains that there is at this time a general paucity of
research in animal models of bortezomib-induced peripheral neuropathy, and there
is little agreement between researchers as to what may drive the observed condition
that is modeled.
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1.7.

Glial Involvement in Neurotransmission
Glia are commonly thought to contribute to neuronal cell function in ways that

do not directly involve them in neuronal synaptic transmission. This should not
suggest, however, that they do not play an important role in this process. Taking into
consideration their role as modulators of inflammatory immune function, microglia
are prevalent in many situations of insult, injury, or otherwise negatively altered
function (Graeber, 2010; Smith, 2013; Eyo and Dailey, 2013). Astrocytes, the glial
cells responsible for neurotransmitter recycling and metabolite production for nearby
nerve terminals, have a clear role synaptic sensitization. First of all, astrocytes
express multiple types of neurotransmitter receptors, including many that are
relevant to neuropathic pain, such as substance P receptors, NMDA receptors, and
metabotropic glutamate receptors (Porter and McCarthy, 1997). These are sufficient
to drive astrocyte activation in response to high levels of synaptic neurotransmitters.
Astrocyte activation is characterized by changes such as increased GFAP surface
marker expression, increased connexin 43 expression, and decreased expression or
function of the glutamate transporters GLT-1 and GLAST. GLT-1 and GLAST are
responsible for clearing neurotransmitter from the synapse following a synaptic
event, and loss of function in these may have stark effects on synaptic transmission
(Samuelsson et al., 2000; Vandenberg and Ryan, 2013; Nicholson, Gilliland, and
Winkelstein, 2014). Decreased glutamate transporter function results in lingering
amounts of glutamate within the synapse. This increases the probability of an action
potential, and greater levels of glutamate transporter dysfunction can even result in
persistent firing of the postsynaptic cell (Campbell and Hablitz, 2004). There is even
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some recent evidence concerning a greater role for astrocytes with regard to
synaptic events: the binding of glutamate onto astrocyte glutamate receptors results
in elevated intracellular Ca2+, which may be followed by subsequent release of
glutamate from the astrocyte itself (Parpura et al., 1994; Haydon, 2001; Nie, Zhang,
and Weng, 2010). It is furthermore possible for this glutamate release into the
synaptic cleft to be sufficient to create an excitatory postsynaptic potential (Parpura
and Zorec, 2010). This has been termed ―gliotransmission,‖ but the concept is still
relatively new and not widely accepted. Even so, it is apparent that sensitization of
synapses such as may be the case in chronic pain may be due in part to a positive
feedback loop between astrocytes and neurons. Increased signaling may drive
astrocyte activation, which may result in decreased glutamate transport and
therefore foster greater signaling.
The importance of glutamate transport with regard to regular synaptic events
is clear. Furthermore, it indicates a possible role for astrocytes with specific regard to
chronic pain sensitization. There is evidence within the spinal cord that a type of
central sensitization which could be induced by these glutamate transporters occurs
in dorsal horn neurons. Spinal cord wide dynamic range (WDR) neurons show
increased firing rates and persistent after-discharges in both injury and
chemotherapy-based neuropathic pain models in response to both noxious and nonnoxious stimuli (Yakhnitsa, Linderoth, and Meyerson 1999; Sotgiu and Biella 2000;
Weng, Cordella, and Dougherty, 2003; Cata, Weng, and Dougherty 2006). The
increased firing in response to non-noxious stimuli provides a strong argument for
central sensitization occurring, and the persistent after-discharges likely indicates
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persistent synaptic glutamate. Importantly, the same types of stimuli that show
altered behavioral responses in these studies evoked these kinds of enhanced and
persistent responses from WDR neurons, indicating a link between the two.
Although microglia are not usually thought of as directly impacting synaptic
transmission, their inflammatory activity may play a role in sensitization of neurons.
However, it seems that this is not a unique aspect of microglia, but something that
astrocytes may contribute to, as well. Following activation of astrocytes or microglia,
either of these cell types will increase transcription of proinflammatory cytokines and
chemokines via p38, JNK, or ERK MAPK signal cascades (Milligan and Watkins,
2009). The transcription and subsequent release of cytokines and chemokines such
as IL-1β, IL-6, TNFα, CCL2, CCL7, and PGE2 from astrocytes and microglia serve
not only to induce further glial activation, but also bind to receptors on nearby
neurons to sensitize neurons directly (Watkins, Milligan, and Maier, 2001; Marchand,
Perretti, and McMahon, 2005; Gao and Ji, 2010a; Huang et al., 2014; Zhu et al.,
2014).
Any effect that astrocytes may have on synaptic transmission, neuronal
sensitization, or inflammatory activity may be further exacerbated by communication
between astrocytes. In order for astrocytes to communicate in a unified network,
they form a functional syncytium with the other astrocytes around them via gap
junctions composed of connexin 43 (Cx43) in gray and white matter and connexin 30
(Cx30) in the gray matter alone (Nagy and Rash, 2000). This allows for the
propagation of signals between astrocytes, such as the conduction of intracellular
Ca2+ that allows for direct release of glutamate (Giaume and Venance, 1998). In
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circumstances of insult or injury, the permeability of these gap junctions increases,
and the connexins themselves become upregulated (Chew et al., 2010; Wu et al.,
2012). Not only does this increase transmission of Ca2+ between astrocytes, but it is
also accompanied by the propagation of prostaglandins and other inflammatory
mediators that result in a vasodilatory response (Wu et al., 2012). The combined
potential for increased glutamate release and inflammatory responses that could
sensitize neurons or induce cytotoxicity make Cx43 an attractive target in the context
of neuropathic pain. Inhibition of Cx43 has correlated with the prevention of the
development of pain and neuronal cell death in multiple models, including CCI,
sciatic inflammatory neuropathy, mustard oil-induced inflammatory pain, focal
cerebral ischemia, and SCI (Spataro et al., 2004; Chew et al., 2010; Chiang et al.,
2011; Wu et al., 2011; Wu et al., 2012). Although these findings have largely been
restricted to injury-based models, our own lab has been successful in preventing
oxaliplatin-induced peripheral neuropathy using the gap junction decoupler
carbenoxolone (Yoon et al., 2013). Not only does the implication of astrocytic gap
junctions in neuropathic pain provide a degree of mechanistic understanding, but it
suggests a necessary role for astrocytes in the development of a neuropathic pain
condition. Whether or not the findings in glutamate transporters and connexins are
generalizable to all forms of neuropathy has not yet been firmly established, but the
involvement of glia in neuropathic pain is becoming increasingly clear.
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1.8.

Minocycline as an Anti-Inflammatory Drug
Minocycline is a tetracycline derivative that was originally developed for its

use as an antimicrobial drug, but it soon became clear that minocycline had potential
for a broad spectrum of therapeutic uses apart from its use as an antibiotic (GarridoMesa, Zarzuelo, and Gálvez, 2013). Animal studies have shown positive effects
resulting from minocycline treatment in multiple sclerosis, ALS, Parkinson’s disease,
Huntington’s disease, spinal cord injury, schizophrenia, and mood disorders,
although transitions into clinical trials have not been universally successful (Yong et
al., 2004; Plane et al., 2010; Dodd et al., 2013). Beneficial effects were observed in
brain ischemia, spinal cord injury, multiple sclerosis, and schizophrenia in clinical
trials. ALS, Huntington’s disease, and Parkinson’s disease trials were unsuccessful.
The mechanisms by which minocycline affects such a diverse array of conditions is
still uncertain, but a generalized anti-inflammatory mechanism would explain its
efficacy in most of these disorders. Indeed, minocycline has been shown to
downregulate levels of proinflammatory cytokines such as CCL2, IL-6, and IL-1β
independently of its antibiotic activity (Kielian et al., 2007; Henry et al., 2008).
The regulation of inflammatory mediators has made minocycline a subject of
interest in neurodegenerative and neuropathic pain models, as inappropriate levels
of inflammation contribute to neuronal cell death following injury, ischemia, infection,
or other forms of insult (Beattie 2004; Hailer, 2008; Ramesh, MacLean, and Phillipp,
2013; Shastri, Bonifati, and Kishore, 2013). To this end, treatment with minocycline
in both animals and patients with spinal cord injury shows promise, improving both
motor function and sensory scores over time (Festoff et al., 2006; Casha et al.,
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2012). Infiltrating microglial cells are a potential locus of this kind of damage, and
minocycline treatment has been shown to be effective in reducing this kind of
infiltration and glial activation (Zemke and Majid, 2004; Beattie 2004; Hailer, 2008). It
is partly because of this activity that minocycline has gained a reputation in glial
research as a selective inhibitor of microglia. However, it is important to note that the
production of cytokines and chemokines targeted by minocycline includes some that
are also produced by cells other than microglia, including the expression of IL-6 and
CCL2 by astrocytes (Thompson and Van Eldik, 2009; Ramesh, MacLean, and
Phillipp, 2013; Zhu et al., 2014). Minocycline may therefore prove effective in the
treatment of disorders driven by any cell type expressing proinflammatory mediators,
even in cases where there is not any observed activation of microglia. Furthermore,
there is also the possibility that minocycline exerts its neuroprotective and
antinociceptive effects by acting on neurons directly. It has been observed that
cultured neurons treated with minocycline show depressed glutamatergic currents
(Gonzalez et al., 2007), which could reduce excitotoxicity in neurodegenerative
models or persistent firing observed in neuropathic pain models.

1.9.

Summary
Neuropathic pain can refer to many types of maladaptive chronic pain

conditions brought about by damage or insult to the nerves or the CNS. These
neuropathies may occur through traumatic injury to affect a localized region, or they
may be systemic, resulting in a more widespread effect. Chemotherapy-induced
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peripheral neuropathy is any neuropathy that occurs as a result of chemotherapy
treatment. Like other systemic neuropathies, symptoms may include a combination
of painful and non-painful symptoms that are usually in a stocking-and-glove
distribution. Sensory symptoms can become so severe in CIPN as to limit effective
treatment. Treatments to manage these symptoms are usually not very effective.
Because treatment is scheduled in advance, it may be possible to develop
preventative strategies pending a better mechanistic understanding of CIPN.
Bortezomib, a proteasome inhibitor drug, is one chemotherapeutic agent that can
cause CIPN. Its anti-tumor activity is poorly understood, but it may exert its effects
through cell cycle arrest, ER-mediated apoptosis, or several other mechanisms.
Even less is known about how it may induce CIPN.
Bortezomib-induced peripheral neuropathy (BIPN) usually occurs within the
first 3-5 cycles of treatment and may affect about 37% of bortezomib-treated
individuals. Patients experiencing BIPN may show spontaneous numbness and
tingling sensations and altered sensitivity or painful sensation to mechanical,
thermal, and cold stimuli. These symptoms occur in both the hands and feet, usually
with the greater effects occurring in the feet.
Recent findings in animal models suggest that there may be a correlation
between CIPN and astrocyte activation. There are several means by which
astrocytes may contribute to observed symptoms in CIPN, including altered activity
of cytokines, gap junctions, and glutamate transporters. Such changes have been
shown in other animal models of CIPN, but it is unknown if these occur in the
bortezomib model, as well. One or more of these may contribute to BIPN, possibly
25

through modulation of signaling in the dorsal horn. Cytokines may directly sensitize
neurons or exert many other possible effects. Increases in astrocytic gap junctions
may result in increased calcium flow between cells. This may result in release of
glutamate directly from astrocytes. Decreases in glutamate transporter expression or
function could inhibit glutamate reuptake. This would foster increased or persistent
signaling within synapses. Any or all of these could create enhanced or spontaneous
sensations such as those seen in patients (Cata et al., 2007). Astrocytes therefore
have multiple potential means by which they may contribute to the BIPN model and
CIPN as a whole. Thus, the central hypothesis of the present work is that astrocyte
activation is correlated with behavioral changes in CIPN in a manner that may
contribute to these changes in behavior.
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2.

CHANGES IN BEHAVIORAL RESPONSES AND WDR NEURON

ELECTROPHYSIOLOGY IN BIPN
Content in this chapter is based on the following publication with permission from the
publisher:
Robinson CR, Zhang H, Dougherty PM (2014) Altered discharges of spinal neurons
parallel the behavioral changes shown in rats with Bortezomib related chemotherapy
induced peripheral neuropathy. Brain Res pii: S0006-8993(14)00816-6.
License No.: 3414340341956
2.1.

INTRODUCTION
In order to determine whether astrocyte activity is correlated with behavioral

changes in the animal model of BIPN, it was first necessary to characterize how the
responses to stimuli in behavioral tests may be altered in this model. At the time that
this research was conducted, it was unknown whether bortezomib treatment would
produce a condition like those seen in another drug model of CIPN, or whether it
would instead affect a different set of behaviors. The hypothesis of this work was
therefore that treatment with bortezomib in a rat model would produce behavioral
changes indicating a condition similar to the CIPN symptoms observed in patients.
This was tested by conducting multiple behavioral tests representing reflexive
responses to multiple types of stimuli and a test of motor ability, then verifying
whether observed behaviors were supported by a corresponding alteration in
stimulus-evoked neuronal responses. While behavioral changes did not match
exactly with patient symptoms, bortezomib treatment in rats did produce robust
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mechanical hypersensitivity that was accompanied by increased firing and afterdischarges in spinal wide dynamic range neurons.
Bortezomib is a drug that was originally developed for the treatment of
multiple myeloma. It was developed for its activity as a proteasome inhibitor, and it is
the first such drug to be approved for use as a chemotherapeutic agent. Bortezomib
treatment may occur in single-agent therapy, but it is more frequently used in
combination with other drugs for increased efficacy (San Miguel et al., 2008;
Kaufman et al., 2010). Although the side effects of bortezomib treatment may be
diverse, chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of
particular concern (Aghajanian et al., 2002; Kane et al., 2006). The distribution of
bortezomib-induced peripheral neuropathy (BIPN) is in what is referred to as a
―stocking and glove‖ distribution, with greatest severity localized to fingers and toes
(Cata et al., 2007). As BIPN progresses in severity, physicians may opt for dosereduction strategies or cessation of treatment (Cata et al., 2007; Broyl , Jongen,
Sonneveld., 2012). This strategy is a sub-optimal solution, as it limits the efficacy of
a patient’s treatment when doses are reduced. It is therefore of critical importance to
obtain a greater mechanistic understanding of BIPN. Doing so would allow for the
development of appropriate treatment strategies or for the prevention of BIPN
altogether.
The efficacy of bortezomib as an anti-neoplastic drug was quickly apparent,
and the FDA granted it fast-track approval. Bortezomib binds selectively to the
proteasome, which is responsible for digesting misfolded or obsolete proteins within
the cell. The proteasome consists of two subunits: a regulatory 19S subunit for
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detecting ubiquitylated proteins and a 20S subunit for digesting them. Bortezomib
binds competitively to the latter of the two at its chymotrypsin-like catalytic site,
thereby preventing the normal degradation of proteins (Adams et al., 1999; Adams,
2002; Adams and Kauffman, 2004). Malignant cells are subject to a greater impact
from this inhibition from healthy cells due to a higher metabolic demand and
increased proliferative tendencies. Potential downstream effects of proteasomal
inhibition are diverse, and it is therefore unclear how exactly bortezomib exerts its
effects. One of the favored explanations is that proteasomal inhibition stabilizes
NFκB into its inactive form, IκB (Hideshima et al., 2001; Voorhees et al., 2003). The
effect of this is a blockade in cell cycle progression, preventing cancer cell
proliferation. However, it is also possible that proteasomal inhibition may trigger
apoptosis directly. Inappropriate proteins in excessive amounts put undue stress on
the endoplasmic reticulum. The ER may then trigger a cascade that results in
caspase-mediated apoptosis (Landowski et al., 2005). Bortezomib also has been
shown to directly affect p53 activity. This may then trigger cytochrome c-mediated
apoptosis in the mitochondria (Hideshima et al., 2003; Voorhees et al., 2003).
Furthermore, it is possible that proteasomal inhibition simply disrupts the balancing
act between pro-survival and pro-apoptotic signals in cancer cells. There are even
more possible explanations than those listed here, but any one of these would be a
plausible mechanism. A more likely explanation is that a combination of these
pathways work in concert with one another for bortezomib to produce its effects.
Judging by the diversity of proposed anti-neoplastic mechanisms in
bortezomib, it should come as no surprise that the mechanisms responsible for BIPN
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are also poorly understood. Unfortunately, this also means that direct treatment
strategies are severely hampered. Different chemotherapy drugs may produce
differing neuropathic conditions with modality specificity. Numbness and tingling are
common symptoms, but patient-reported descriptors and objective sensitivity to
different types of stimuli vary between drugs (Cata et al., 2007; Dougherty et al.,
2007; Boyette-Davis et al., 2012). Preclinical data across multiple modalities is
therefore important before a mechanistic understanding can be reached in animal
models of BIPN. The studies in animal models have been few and necessitate
further study (see introduction).
It is uncertain where along the somatosensory tract BIPN originates, but it is
clear that bortezomib cannot cross the blood-brain barrier (Adams, 2002). However,
findings in other CIPN models have shown clear changes in spinal wide dynamic
range (WDR) neuron activity (Cata et al., 2006a; Cata, Weng, and Dougherty,
2008a). Such findings indicate a possibility that some combination of glutamate
transporter dysfunction and central sensitization may contribute to CIPN. If such
findings are also seen in the present model, then this would explain enhanced and
persistent sensations that are observed in patients with BIPN (Cata et al., 2007;
Boyette-Davis et al., 2011a). Thus, the focus of the present study was twofold: first,
to identify a behavioral profile of affected modalities associated with BIPN in the rat
model, and second, to assess whether there is an accompanying change in spinal
wide dynamic range neurons.
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2.2

METHODS

2.2.1. Animals
A total of 61 male Sprague Dawley rats (Harlan) were used. Animals were
housed on a 12hr/12hr light cycle and provided food and water ad libitum throughout
the testing period. All efforts were taken to minimize pain and discomfort in animals,
and all handling and procedures were approved by the institutional review board and
in accordance with institutional ethical standards.

2.2.2. Drugs
All agents were administered by intraperitoneal (i.p.) injection at in equivalent
volumes (0.7mL per injection). Pharmaceutical grade bortezomib (Velcade®,
Millennium Pharmaceuticals) was diluted in saline to the desired concentration.
Dosages of 0.05mg/kg, 0.10mg/kg, 0.15mg/kg, and 0.20mg/kg per injection were
used in the initial behavioral characterization studies. A total of four injections of
each dose were administered on days 1, 3, 5, and 7 of each study resulting in
cumulative doses of 0.20mg/kg, 0.40mg/kg, 0.60mg/kg, and 0.80mg/kg per
treatment. The 0.15mg/kg dose was subsequently defined as the optimal dose in
producing the behavioral changes that was used in the follow-up neurophysiology
studies. Control groups of rats were treated with saline vehicle alone at the same
time intervals.
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2.2.3. Mechanical Sensitivity Testing
Sensitivity to mechanical stimuli was assessed using Von Frey filaments as
previously described (Boyette-Davis and Dougherty, 2011; Yoon et al., 2013). A
range of filaments calibrated to 1g, 4g, 10g, 15g, and 26g of bending force were
used for testing. Filaments were applied to the mid-plantar surface of the hindpaw
until a bend was observed in the filament and held for approximately 1 second. After
a half-hour habituation period, each animal had its mechanical withdrawal threshold
for each foot assessed as the lowest filament in the ascending series at which the
animal responded to at least 50% of six applications. Animals were tested for
baseline response just prior to their first injection of drug (day 1) and the days after
each injection (days 2, 4, 6, and 8). Following this, rats were tested for mechanical
threshold twice weekly for one month, then once weekly until recovery from the
hypersensitivity behaviors, assessed as a return to baseline withdrawal threshold.

2.2.4. Heat Sensitivity Testing
Heat sensitivity in rats was tested using a Hargreaves testing apparatus (Ugo
Basile). An infrared beam was directed to the mid-plantar surface of each hindpaw,
and the latency to withdrawal was measured. This was repeated for three trials per
paw with a 20 second cutoff to prevent tissue damage. Baseline beam intensity was
set to evoke a baseline response between 10-12 seconds. Rats were tested at time
points corresponding to those of dose response testing until day 30.
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2.2.5. Cold Sensitivity Testing
Rats were tested for cold sensitivity via scored responses to application of
acetone. For each trial, 50µL of acetone was applied to the mid-plantar surface of
each hindpaw using a calibrated pipette. The behavior of the rat was observed and
scored for 20 seconds following this application. A score of 1 was assigned for each
rapid withdrawal or flicking of the foot. A score of 2 indicated prolonged (>1 second)
withdrawal, and a score of 3 indicated licking of the hindpaw. Trials were conducted
three times per hindpaw, for a total of six trials per testing period. Cold sensitivity
testing was conducted at the same time points as thermal testing.

2.2.6. Motor Impairment Testing
The potential for motor impairment due to chemotherapy treatment was
assessed by rotarod assay as previously described (Cata, Weng, and Dougherty,
2008b). A rotating wheel was set to increase over time from a speed of 4rpm to
40rpm. Each animal was placed on this accelerating wheel and allowed to walk for
120 seconds or until it fell off of the wheel, at which point the rotating wheel would
shut off automatically. Three trials were recorded per animal per time point with a 5
minute resting period between trials. Time points corresponded to those of thermal
testing.
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2.2.7. In vivo Electrophysiology
All rats used for in vivo electrophysiology treated with bortezomib had
confirmed behavioral hypersensitivity to chemotherapy and were compared to
saline-treated controls. Rats were anesthetized using urethane (1.5g/kg i.p.) and
anesthetic depth was verified by toe pinch for loss of nociceptive reflexes with
supplemental anesthetic given as needed. The L5-6 spinal cord was exposed via
laminectomy and the animal then mounted into a stereotactic frame. The spinal cord
was covered with agar with an opening to allow electrode access that was kept filled
with saline. A parylene-coated tungsten filament electrode (resistance 1.4-1.8MΩ,
Microprobes Inc.) was advanced into the spinal cord using a hydraulic Microdrive.
Cells were isolated using mechanical stimulation of the paw. Wide dynamic range
(WDR) neurons responding in graded fashion to innocuous and noxious stimuli
achieving a signal to noise ratio greater than 5 were selected for study.
Assessment of neuronal activity began with recording of 60 seconds
spontaneous activity. Mechanical stimuli were then applied for 10 seconds each with
30 second inter-stimulus intervals. The stimuli included camel hair brush (1
application/second), 0.07g von Frey filament (1 application/second), 1.4g von Frey
filament (1 application/second), 60g von Frey filament (1 application/second),
venous clip (continual application), and arterial clip (continual application). Spike2
software was used to capture spikes and for off-line analysis of stimulus response
frequencies and afterdischarge rates. The 5 seconds following each stimulus were
used for analysis of afterdischarges.
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2.2.8. Statistics
For all measurements in both behavior testing and electrophysiology, each
representative data point was calculated as the mean value for a given group at the
time point represented. Error bars were then calculated as standard error of the
mean, and significance was determined using a Mann-Whitney test (α = 0.05, 0.025,
0.01). Additionally, a one-way ANOVA with a post-hoc Tukey test was used in
mechanical behavior testing across doses to determine whether the observed
behavior differed versus control and between other doses (P = 0.05, 0.01).
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2.3.

RESULTS

2.3.1. Mechanical Sensitivity

2.3.1.1

0.05mg/kg Bortezomib

Rats treated at the 0.05mg/kg dose of bortezomib had a gradual and slight
onset of mechanical hypersensitivity versus baseline behavior that was determined
in ANOVA to not differ significantly versus controls (Fig. 1A). Nevertheless, this
group was significantly lower versus control at day 19 (naïve: 17.2±2.49g,
bortezomib: 10.4±1.10g), as well as at days 23, 26, and 34. After this point, rats
began to recover from changes in mechanical sensitivity. Although the average
withdrawal threshold was higher for this group at later time points than in salinetreated rats, this difference was not statistically significant, and these rats started
with a higher baseline threshold than the saline-treated group.

2.3.1.2.

0.10mg/kg Bortezomib

Rats treated at the 0.10mg/kg dose of bortezomib showed a significantly
reduced mechanical withdrawal threshold than the saline-treated and 0.05mg/kg
treated groups (P<0.01), but not different from the 0.15mg/kg or 0.20mg/kg groups.
This group first showed statistically significant mechanical hyperalgesia versus
controls at day 6 (naïve: 19.3±2.56g, bortezomib: 13.9±1.54g), after the third
injection of bortezomib (Fig. 1B). Significant differences were also observed at every
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following time point until day 54. Peak severity was observed from day 16 to day 34
(approx. 7.5g). Recovery from changes in mechanical sensitivity was gradual after
this point, with statistically equivalent behavior versus saline-treated rats at days 63
and 69.

2.3.1.3.

0.15mg/kg Bortezomib

Rats treated at the 0.15mg/kg dose of bortezomib showed significantly
lowered withdrawal threshold from the saline-treated and 0.05mg/kg group (P<0.01),
but not from the 0.10mg/kg or 0.20mg/kg groups. This group first showed statistically
significant mechanical hyperalgesia versus controls at day 8 (naïve: 17.3±2.48g,
bortezomib: 11.1±2.41g), after the final injection of bortezomib (Fig. 1C). Significant
differences were also observed at days 12, 19 through 41, and 54. Peak severity
was observed from day 19 to day 34 (approx. 7.5g). Animals began to recover from
mechanical hypersensitivity following this point, with statistically equivalent behavior
versus saline-treated rats at days 47, 63, and 69.

2.3.1.4.

0.20mg/kg Bortezomib

Rats treated at the 0.20mg/kg dose of bortezomib showed significantly
lowered withdrawal threshold from the saline-treated and 0.05mg/kg group (P<0.01),
but not from the 0.10mg/kg or 0.15mg/kg groups. This group first showed statistically
significant mechanical hyperalgesia versus controls at day 19 (naïve: 17.2±2.49g,
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bortezomib: 9.75±1.36g), after the 0.10mg/kg and 0.15mg/kg doses showed similar
differences (Fig. 1D). However, because of a larger error at the day 12 and 16 time
points, the 0.20mg/kg group could not be determined to be significantly different
from either saline-treated rats or rats treated with other doses of bortezomib.
Significant differences versus saline-treated rats were also observed at days 23, 26,
34, 47, and 54. Peak severity was observed at days 23 and 26 (7.25 and 7.36g).
Animals showed highly variable mechanical sensitivity in the time points that
followed, but did not show consistent recovery with statistically equivalent behavior
versus saline-treated rats until days 63 and 69.
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Figure 1.
Bortezomib
produces
mechanical
hypersensitivity in
rats. Mechanical
sensitivity was
assessed by
responses to midplantar application
of von Frey
filaments over
time. A) Saline
treated control
group vs. rats
treated with
0.05mg/kg
bortezomib B)
Saline treated
control group vs.
rats treated with
0.10mg/kg
bortezomib C)
Saline treated
control group vs.
rats treated with
0.15mg/kg
bortezomib D)
Saline treated
control group vs.
rats treated with
0.20mg/kg
bortezomib.
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2.3.2. Heat, Cold, and Motor Behavior
In thermal testing, both saline and bortezomib -treated groups remained at
baseline levels throughout testing until they were sacrificed at day 30, long after
significant differences appeared in rats tested for mechanical hyperalgesia (Fig. 2).
Similarly, bortezomib-treated animals remained in line with saline-treated
counterparts when tested for cold sensitivity throughout the period of testing (Fig. 3).
There was one time point in which bortezomib-treated rats scored significantly
higher than saline-treated rats, but this score was less than 0.5, indicating on
average less than one withdrawal event per test. Peak scores never rose far beyond
a score of 1.0. Rotarod testing showed a lack of motor impairment in animals treated
with bortezomib, as well (Fig. 4). Although some time points showed average
walking times less than the 120 second cutoff time, none of these data points were
significant.
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Figure 2. Bortezomib does not produce thermal hypersensitivity in rats. Thermal
sensitivity was assessed via Hargreaves test, using a focused infrared beam
with an automatic cutoff when interrupted by movement of the rat’s foot. Infrared
intensity was calibrated such that animals would respond on average after 1012 seconds of continuous exposure at baseline, and this intensity was
maintained throughout testing. Withdrawal latencies were obtained three times
per foot per rat per time point. Neither saline-treated nor bortezomib-treated rats
consistently showed an average withdrawal latency significantly below 10
seconds throughout testing, which falls within baseline range.
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Figure 3. Bortezomib-treated rats did not develop cold hypersensitivity. Cold
stimuli were simulated by applying acetone to the mid-plantar surface of each
hindpaw. Responses were scored for each of three trials per foot per rat per
time point. Scores were based on behavior in the 20 seconds following
application of acetone.

42

Figure 4. Bortezomib-treated rats did not develop motor impairment. Rats were
allowed to walk on a rotarod that slowly accelerated from 4-40rpm. Walking time
was recorded either until the rat fell from the wheel or until a 120 second cutoff
was reached.
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2.3.3. Electrophysiology
WDR neurons in bortezomib-treated rats (n=30) showed higher acute
responses and afterdischarges to mechanical stimuli compared against neurons in
control rats (n=22) (Fig. 5). Spontaneous firing of neurons was negligible in both
groups (naïve: 0.036±0.016 spikes/s, bortezomib: 0.13±0.053 spikes/s). Both acute
responses to Brush (naïve: 3.6±0.30 spikes/s, bortezomib: 9.1±0.93 spikes/s) and
afterdischarges (naïve: 0.090±0.052 spikes/s, bortezomib: 1.6±0.32 spikes/s) were
significantly elevated in bortezomib rats. The acute responses to the 0.07g von Frey
stimulus were not significantly different in bortezomib rats (naïve: 1.3±0.16 spikes/s,
bortezomib: 9.2±0.93 spikes/s), but the afterdischarges to this stimulus were
significantly higher (naïve: 0.036±0.036 spikes/s, bortezomib: 0.43±0.16 spikes/s).
Neither the acute response to the 1.4g von Frey filament (naïve: 2.7±0.32 spikes/s,
bortezomib: 3.5±0.42 spikes/s) nor the afterdischarges (naïve: 0.13±0.056 spikes/s,
bortezomib: 0.57±0.15 spikes/s) were significantly different from control rats. The
responses to the 60g von Frey filament were significantly higher in bortezomib
(naïve: 4.7±0.40 spikes/s, bortezomib: 7.5±0.73 spikes/s), as were the
afterdischarges (naïve: 0.20±0.13 spikes/s, bortezomib: 1.2±0.29 spikes/s). Venous
clip (light skin compression) responses were significantly higher in bortezomib
(naïve: 5.3±0.77 spikes/s, bortezomib: 9.6±0.67 spikes/s), as were the
afterdischarges (naïve: 0.65±0.26 spikes/s, bortezomib: 3.5±0.62 spikes/s). Arterial
clip (painful skin compression) responses were significantly higher in bortezomib
(naïve: 7.5±0.98 spikes/s, bortezomib: 14±1.2 spikes/s), as were the afterdischarges
(naïve: 1.0±0.31 spikes/s, bortezomib: 5.9±0.80 spikes/s).
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Figure 5. Bortezomib-treated rats developed enhanced firing responses in in
vivo spinal WDR neuron electrophysiology. Spikes during and after stimulus
application were quantified for spontaneous activity, brush application, three
sizes of von Frey filament (0.07g, 1.4g, and 60g), venous clip (VC), and arterial
clip (AC).
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2.4.

DISCUSSION
The dose-response data generated in the present study indicate that even

doses below those used for chemotherapy in patients are sufficient to induce the
BIPN model. However, doses approximating the therapeutic dose were more
effective in generating this condition. Exceeding therapeutic doses did not increase
the sensitivity further. A similar trend is observed in patients. 37% of patients will
develop BIPN within 5 cycles of treatment, but those that do not develop BIPN by
this time are unlikely to develop it at all (Kane et al., 2006; Richardson et al., 2006;
Cavaletti and Jakubowiak, 2010; Broyl, Jongen, Sonneveld, 2012). It is therefore
possible that bortezomib exerts its neuropathic effects based on whether a threshold
is reached, rather than in a manner that directly correlates with dosage. However,
dose reduction was reported to be effective in reducing all BIPN symptoms if
implemented at the first signs (Richardson et al., 2006). This may be a matter of
addressing emergent BIPN before the threshold is fully reached, as the present data
show a lesser effect at the lowest dose that resolves more quickly.
Bortezomib-treated animals were similar to animals treated with paclitaxel in
the time course of neuropathic symptoms, which also showed a recovery at
approximately 60 days (Cata, Weng, and Dougherty, 2008b). Animals treated with
oxaliplatin followed a similar trend and took over two months to recover (Xiao,
Zheng, and Bennett, 2012). This trend is not at all surprising, considering that it may
take months for patients to recover by even one grade of neuropathy (Cavaletti and
Jakubowiak, 2010; Broyl, Jongen, Sonneveld, 2012). The genetic homogeneity of
the strain of rat used may be a contributing factor to the time course and relatively
46

stable recovery time in the current study. On the other hand, the pharmacokinetics of
bortezomib show a full return of proteasomal function in 48-72 hours (Adams, 2002).
It is therefore important in future studies to consider the possibility of a long-lasting
signal cascade maintaining BIPN that is not dependent on continued proteasomal
inhibition.
The present data show a clear change in mechanical sensitivity in the BIPN
model. However, there were no changes to other modalities observed. Bortezomib
therefore differs from other drugs in the profile of affected behaviors, as paclitaxel
induces thermal sensitivity in rats (Dina et al., 2001; Cata, Weng, and Dougherty,
2008b), and oxaliplatin is capable of inducing sensitivity to thermal and cold stimuli
(Joseph and Levine, 2009; Xiao, Zheng, and Bennett, 2012). Patients with BIPN
showed a different profile than what was observed in rats in the present study, with
decreased sensitivity to thermal stimuli, increased sensitivity to cold stimuli, and
some degree of fine motor impairment (Cata et al., 2007). It is unclear whether these
discrepancies are due to differences between the tests used in humans versus rats,
or perhaps if there are differences in how the species respond to the drug. However,
it is important to note that the tests used to assess changes in the present study
have been successful in other models. It is therefore unknown what causes the
mechanical sensitivity to be the sole form of behavior affected in the present study,
but nevertheless important to note that this distinguishes bortezomib from other
agents.
The alterations observed in WDR neurons were robust, but the fact remains
that bortezomib cannot cross the blood-brain barrier. This finding strongly suggests
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that bortezomib initiates damage to primary afferents that then act on the spinal
cord. This could occur through increased presynaptic signaling, as continual firing of
these primary afferents could result in spinal central sensitization (Rygh et al., 1999;
Ji et al., 2003). The present electrophysiological data would suggest something akin
to central sensitization, although it cannot be said with certainty that it results from
increased presynaptic signaling. The same effect could also occur due to
downregulation of astrocytic glutamate transporters or by increases in sensitivity at
the postsynaptic cell if there is input from outside of the blood-brain barrier. The
glutamate transporter hypothesis in particular could account for the persistent afterdischarges because of the persistence of synaptic glutamate. However, there must
still be some signal from outside of the spinal cord to initiate such a change. The
activity of spinal glial cells may also contribute to the changes observed in the
present study through the release of proinflammatory cytokines. This has been of
particular interest in similar models, and the diverse role of these cytokines may
contribute to pain in multiple ways (Clark, Old, and Malcangio, 2013; Ji, Berta, and
Nedergaard, 2013). Our lab has previously shown alterations of glutamate
transporters in other models of CIPN in models that show similar changes in WDR
responses, and ongoing work is investigating this possibility of a cytokine cascade
(Cata et al., 2006a; Cata, Weng, and Dougherty, 2008a; Zhang et al., 2012).
Bortezomib clearly possesses some mechanistic differences from other drugs
in order to produce a distinct neuropathic condition, but how this occurs is unknown.
In summary of the present study’s findings, bortezomib induced hypersensitivity to
mechanical stimuli and increases to WDR neuron firing and after-discharges. Other
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modalities investigated were not affected. Precisely how bortezomib induces the
BIPN model will require a significant amount of future study, but there may be some
overlap in this model with other models of CIPN. The similarity in WDR neuronal
responses suggest a degree of overlap, and future studies involving glial
mechanisms seen in other models would suggest further similarities. The findings in
the present study now provide a foundation for mechanistic studies, as proposed
mechanisms can be compared for their effects on the modalities presently identified.
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3.

SPINAL CORD GLIAL ACTIVATION PROFILE IN BIPN

Content in this chapter is based on the following publication with permission from the
publisher:
Robinson CR, Zhang H, Dougherty PM (2014) Astrocytes, but not microglia, are
activated in oxaliplatin and bortezomib-induced peripheral neuropathy in the rat.
Neuroscience pii: S0306-4522(14)00459-X.
License No.: 3413230352490
3.1.

INTRODUCTION
In order to show a correlation between observed changes in behavior and the

activity of astrocytes, it was important to track the course of reactive gliosis in the
bortezomib model. To truly establish a connection between these two phenomena, it
is necessary for the data to support three conclusions: astrocytes are activated in
animals that display appropriate behavioral changes, astrocytes are not activated in
controls that do not develop behavioral changes, and the prevention of behavioral
changes also prevents astrocyte activation. The hypothesis in this chapter was
therefore that astrocytes are activated in chemotherapy-treated animals that develop
mechanical sensitivity and that both phenomena are prevented by co-treatment with
an inhibitor of glial activation. The data were in support of this hypothesis, and it was
also verified that microglia were not similarly activated at observed time points. This
further suggests that the astrogliosis occurs as its own phenomenon, rather than as
an extension of other glial functions.
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Current research on neuropathic pain is hampered by a limited mechanistic
understanding regarding both its induction and maintenance. However, emerging
evidence suggests a role for a glial-driven release of proinflammatory cytokines that
may drive sensitization of spinal neurons (Graeber, 2010; Sivilotti and Woolf, 1994;
Ji and Suter, 2007; Miller et al., 2009). Microglia have become particularly popular
in this regard due to a prominent role in immune and inflammatory function
(Graeber, 2010; Ji and Suter, 2007). In spite of this popularity of microglia, it is
important to note that astrocytes have been known to play a role in injury models for
decades now (Garrison et al., 1991). To note a common activation profile across
multiple models of pain may suggest common mechanisms in neuropathic pain,
even in spite of the vastly different forms of insult that may contribute to such a
disorder.
Like many other forms of small-fiber neuropathies, chemotherapy-induced
peripheral neuropathy (CIPN) presents with a spectrum of dysesthesias and
paresthesias that include increased pain sensitivity, spontaneous pain, tingling,
burning sensations, and numbness, among other descriptors (Dougherty et al.,
2007). The exact presentation of CIPN in patients may vary from one drug to
another, with some modalities affected more or unaffected entirely (Cata et al.,
2006b; Cavaletti and Marmiroli, 2010). Thus, effective development of therapeutic
strategies requires a more exact understanding of CIPN and how it may be distinct
from other forms of pain. One such distinction was recently discovered when it was
found that microglia are not activated in animal models of CIPN as they are in nerve
injury models (Zheng, Xiao, and Bennett, 2011; Zhang et al. 2012). Such a finding is
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somewhat controversial, considering that popular theory holds that microglia play a
pivotal role across all types of chronic pain. This assumption may not be entirely
accurate, as there is some evidence that astrocytes may be both necessary and
sufficient to induce neuropathy in some models (Gao and Ji, 2010b; Hald, 2009). In
fact, our own work has reported astrocyte activation in paclitaxel without any
apparent activation of microglia (Zhang et al., 2012). The aim of the current study is
to determine whether a similar trend is also seen in other CIPN models, suggesting
a centralized role for glia in CIPN as a whole.
Minocycline is an antibiotic and anti-inflammatory drug that has previously
produced an abrogation of sensitivity behaviors in some models (Hua et al., 2005;
Ledeboer et al., 2005; Guasti et al., 2009). Although this was previously assumed to
be a result of microglial inhibition, additional work has shown an effect following
minocycline treatment in models that show no activation of microglia (Boyette-Davis
and Dougherty, 2011; Boyette-Davis et al., 2011b; Cata, Weng, and Dougherty,
2008b; Zheng, Xiao, and Bennett, 2011). These findings point to a generalized antiinflammatory role for minocycline, rather than a selective microglial inhibitory effect.
This would explain why minocycline produces an effect in microglia, but it could also
potentially affect any inflammatory mechanisms in astrocytes in a similar manner.
The current study therefore also used minocycline in co-treatment with bortezomib
and oxaliplatin to test whether these animals differed from those treated with their
respective vehicles. If minocycline successfully impacts both behavioral and glial
changes in the animal CIPN model, then it is possible that there is a direct
connection between the two observed effects. Although this has not been
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investigated in the bortezomib model, minocycline was previously shown to be
successful in preventing mechanical sensitivity in oxaliplatin-treated animals
(Boyette-Davis and Dougherty, 2011). The present study therefore has two major
goals: first, to ascertain whether astrocytes are selectively activated in oxaliplatin
and bortezomib treatment, and second, to determine whether co-administration of
minocycline has an effect on behaviors and glial activation in bortezomib-treated
animals.
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3.2.

METHODS

3.2.1. Animals
All procedures were reviewed and approved by the M.D. Anderson
Institutional Animal Care and Use Committee and were in accordance with the
guidelines established by the NIH and the International Association for the Study of
Pain. 111 Male Sprague-Dawley rats between 60 and 75 days of age upon
beginning of treatment (300-350 g) were used for all experiments. Rats were housed
in a facility with a 12-h light/dark cycle and were given food and water ad libitum. All
efforts were taken at each stage of the experiments to limit the numbers of animals
used and any discomfort to which they might be exposed.

3.2.2. Drugs
All drugs were administered by intraperitoneal injection in a volume of 0.5 ml.
Oxaliplatin (Tocris Bioscience) was administered in dextrose vehicle at a dose of
2mg/kg on days 1, 3, 5, and 7 of experimentation for a cumulative dose of 8mg/kg as
previously described (Boyette-Davis and Dougherty, 2011). Bortezomib (Millennium
Pharmaceuticals) was administered in saline vehicle at a dose of 0.15 mg/kg on
days 1, 3, 5, and 7 of experimentation for a cumulative dose of 0.60 mg/kg. Groups
treated with minocycline hydrochloride (Sigma Aldrich) were injected daily with 25.0
mg/kg minocycline in saline vehicle beginning at day 0 and continuing daily through
day 8 (one day past chemotherapy treatment) of experimentation for a cumulative
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dose of 225mg/kg. Control groups were injected with an equivalent volume of
appropriate vehicles (saline for bortezomib or dextrose for oxaliplatin).

3.2.3. Surgery
As a positive control for activation of both astrocytes and microglia, 6 rats
received spinal nerve ligation (SNL) surgery (Kim and Chung, 1992). The rats were
anesthetized using inhaled isoflurane (3-4%) to an adequate depth, verified by loss
of nociceptive and blink reflexes. The L5 spinal nerve was exposed immediately
distal to the dorsal root ganglion and then ligated with 6-0 silk suture. The wound
was then closed in layers using vicryl suture and the skin closed with wound clips.
The animal was monitored during recovery until it resumed normal activity. Another
6 rats received sham surgery, in which the L5 nerve was exposed, but not ligated.

3.2.4. Behavior Testing
Sensitivity to mechanical stimuli was assessed in all animals using von Frey
filaments (Boyette-Davis and Dougherty, 2011; Boyette-Davis et al., 2011b).
Filaments calibrated to 4g, 10g, 15g, and 26g bending force were applied 6 times
each to the mid-plantar surface of each hindpaw in order to determine the filament
corresponding to the animal’s response threshold. Animal identifiers were concealed
prior to testing to ensure blinding of the tester. Application of filaments began
following a half-hour habituation period with the lowest (4g) filament. This was
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followed by other filaments of increasing bending force until a withdrawal threshold
was obtained. Rats were allowed a resting period of 5 to 10 minutes between
filaments in order to minimize the possibility of responses due to anxiety during
testing. Filaments were applied with steady force until bending of the filament was
observed and held for approximately 1second. A response was evaluated as a rapid
withdrawal of the paw. The threshold for sensitivity to mechanical stimuli was
recorded as the bending force of the filament for which at least 50% of applications
elicited a response. The mean of this threshold was reported for each treatment
group at each time point. Error was reported as standard error of the mean (SEM),
and significance was tested at critical time points (those in which the errors of the
two groups did not overlap or in which there was minimal overlap of errors) using
Mann-Whitney tests.
The persistence of sensation was also measured based on von Frey
responses that evoked exaggerated behaviors such as prolonged lifting, shaking, or
licking of the paw. Out of the responses used to determine the 50% withdrawal
threshold, the number of these that evoked an exaggerated response was recorded
and expressed as percent of total responses. Error was reported as standard error
of the mean (SEM), and significance was tested in bortezomib and bortezomib +
minocycline groups versus saline-treated controls using Mann-Whitney tests.
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3.2.5. Tissue Collection
At the conclusion of the behavioral testing, animals with confirmed CIPN or
SNL mechanical hyper-responsiveness were overdosed with sodium pentobarbital
(150mg), then perfused intracardially with room temperature heparinized saline,
followed by cold 4% paraformaldehyde in 0.1M phosphate buffer. Spinal cords were
removed and post-fixed in 4% paraformaldehyde at 4oC overnight, then moved to
15% sucrose the following day. Tissue was then moved after 24h to 30% sucrose for
a minimum of 48h as a cryoprotectant. The lumbar enlargement was mounted and
the L5 segment cut in a cryostat at a thickness of 30μm.

3.2.6. Immunohistochemistry
Spinal cord slices were washed in phosphate-buffered saline (PBS) for 6
washes lasting 15 minutes each and then blocked in normal donkey serum (5% NDS
and 0.2% triton X in PBS). Slices were incubated overnight at 4oC with primary
antibodies against GFAP (mouse anti-rat 1:1000, Cell Signaling Technology) or OX42 (mouse anti-rat 1:1000, AbD Serotec). Slices were washed the following day in
PBS for 6 washes lasting 15 minutes each, then incubated with either FITCconjugated donkey anti-mouse secondary antibody for the GFAP primary antibody
(1:500, Jackson Immunoresearch) or Cy-3-conjugated donkey anti-mouse
secondary antibody for the OX-42 primary antibody (1:500, Jackson
Immunoresearch) for 2 hours at room temperature. Slices were washed for a final
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course of 6 washes lasting 15 minutes each, then mounted onto glass slides using
Vectamount medium.

3.2.7. Quantification of Immunohistochemistry
Slices were viewed and images captured using light and fluorescent
illumination at 10X using a Nikon Eclipse E600 microscope. These images were
layered with both a fluorescent and bright field image to allow toggling between
filters to draw a region of interest limited to but containing the full dorsal horn. The
region of interest was drawn using the light image to avoid bias from fluorescent
imaging. The filter was then changed to fluorescence imaging, maintaining the
location of the region of interest. A region containing only background signal was
selected within the slice, and the corresponding level of fluorescence intensity was
analyzed using NIS Elements software (Nikon, USA). Background was subtracted
and the resulting signal was then expressed as intensity within the region of interest
in pixels/μm2. For each treatment group, the mean of these values was calculated
and expressed as a percent versus the control group of the same time point. Error
was expressed as the combined standard error of the mean (SEM) for treatment and
control groups to account for variability within controls. Significance was determined
via Mann-Whitney test (α = 0.05, 0.025, 0.01).
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3.3.

RESULTS

3.3.1. Behavior
Mechanical sensitivity as described by von Frey filament testing was taken for
rats treated with bortezomib, bortezomib + minocycline, saline, oxaliplatin, oxaliplatin
+ minocycline, dextrose, SNL (ipsilateral and contralateral to surgery), and sham
surgery (ipsilateral and contralateral to surgery). Baseline von Frey withdrawal
thresholds were not significantly different between groups treated with bortezomib
(21.2 ± 1.5g), saline (21.2 ±1.4g), or bortezomib + minocycline (23.3 ± 1.7g). Rats
treated with bortezomib showed a steady decrease in withdrawal thresholds to von
Frey stimuli starting at day 6 that became significantly different from vehicle-treated
controls at day 12 (bortezomib = 10.3 ± 1.2g/ saline = 19.8 ± 2.1g) and reached
peak severity at days 20 (bortezomib = 11.0 ± 2.6g/ saline = 19.4 ± 2.3g), 24
(bortezomib = 5.7 ± 1.1g/ saline = 18.6 ± 3.2g) through day 28 (bortezomib = 9.4 ±
1.3g/ saline = 18.3 ± 2.7g) (Fig. 6A). The rats showed a gradual recovery in
withdrawal threshold after day 41 until a complete recovery was observed at day 69
(bortezomib = 15 ± 0g/ saline = 17.8 ± 3.8g). Rats co-treated with minocycline
showed no difference in withdrawal threshold versus saline-treated controls at any
time point.
Baseline von Frey filament thresholds were not significantly different between
groups that were treated with oxaliplatin (20.5 ± 1.6g), dextrose (22.3 ± 1.5), or
oxaliplatin + minocycline (20.5 ± 2.3g). Oxaliplatin-treated rats showed a significant
decrease in threshold following treatment at day 14 (oxaliplatin = 12.0 ± 1.4g/
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dextrose = 20.6 ± 2.8g) (Fig. 6B), but were not observed for recovery. As with
bortezomib, co-treatment with minocycline in oxaliplatin-treated rats prevented this
change (Boyette-Davis and Dougherty, 2011).
SNL rats showed a sharp decrease in response threshold in the paw
ipsilateral to surgery on day 3, the first day of testing following surgery (6.0 ± 1.3g
ipsilateral/ 16.0 ± 2.2g contralateral) (Fig. 6C). This increased sensitivity was
maintained a week following surgery (3.5 ± 0.5g ipsilateral/ 17.0 ± 3.0g contralateral)
until animals were sacrificed on day 14 (5.0 ± 1.0g ipsilateral/ 19.6 ± 2.9g
contralateral). There was no change in sensitivity between ipsilateral or contralateral
paws in sham surgery rats.
The percent of persistent withdrawal responses during von Frey testing was
exaggerated by chemotherapy treatment, with bortezomib-treated rats showing a
significantly higher percentage of exaggerated withdrawals at days 7 and 28 versus
saline-treated controls (Fig. 6D). Bortezomib animals co-treated with minocycline did
not differ significantly from saline-treated controls at any time point.
In summary, animals treated with bortezomib or oxaliplatin, as well as those
with SNL surgeries, developed marked increases in sensitivity to von Frey filament
stimulation as an assay of mechanical sensitivity. The bortezomib-treated rats were
tested until the behaviors recovered to baseline, as this model has not been
described in as much detail. Animals treated with minocycline in both bortezomib
and oxaliplatin models did not differ in mechanical sensitivity from vehicle-treated
animals.
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Figure 6. Verification of
changes in mechanical
sensitivity using von Frey
filament withdrawal
thresholds. (A)
Bortezomib-treated rats
(n=16) showed an
decrease in withdrawal
thresholds compared to
saline-treated controls
(n=15), that was not
observed in rats cotreated with minocycline
(n=8). (B) Rats treated
with spinal nerve ligation
(SNL) (n=6) showed a
marked decrease in
withdrawal thresholds in
feet ipsilateral to ligation
versus contralateral, and
sham surgery rats (n=6)
showed no such change.
(C) Oxaliplatin-treated
rats (n=12) showed an
decrease in withdrawal
thresholds compared to
dextrose-treated controls
(n=12) that was not
observed in rats cotreated with minocycline
(n=6). (D) Bortezomibtreated rats (n=12)
showed increases in the
percent of persistent
withdrawals during von
Frey stimulation versus
saline-treated rats (n=11)
that were not observed in
animals co-treated with
minocycline (n=12).
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3.3.2. Qualitative Changes in Glial Morphology and Distribution
Although measures used in the present study were limited to overall
expression of glia, several qualitative changes in spinal glial morphology were also
noted. Activated astrocytes and microglia showed increased surface marker
expression, as well as an observed increase in density and number of processes
and swollen cell bodies when viewed under high magnification (Fig. 7). These
changes were not restricted to the dorsal horn, where GFAP and OX-42 expression
were quantified, but activation was distributed in an apparently homogenous manner
throughout the ventral horn and other spinal cord gray matter, as well (Fig. 8-10).
The observed changes in morphology are notable as a trend that is not restricted to
a single model, but as generalized trends in all models that showed increases in
GFAP or OX-42 markers. These changes observed in astrocytes applied to all three
models, whereas the changes in microglia morphology only applied to the SNL
model in which they showed increases in OX-42 expression.
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Figure 7. Activated astrocytes and microglia are marked with greater
arborization and hypertrophy versus inactive counterparts. Astrocytes shown
are from day 30 saline treated (left) and bortezomib-treated (right) dorsal horn.
Microglia shown are from sham surgery (left) and SNL surgery (right) dorsal
horn ipsilateral to surgery.
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3.3.3. Astrocyte Activation Following Bortezomib Treatment
Fluorescent intensity of GFAP immunohistochemistry in bortezomib-treated
rats was found to be significantly higher versus saline-treated controls at multiple
time points. Staining intensity for GFAP showed statistically significant increases at
day 7 (111 ± 3.9% of control), day 14 (113 ± 5.1% of control), and day 30 (162 ±
11.5% of control) (Fig. 7 and Fig. 11A). GFAP staining intensity was not statistically
significant in bortezomib at day 69 (94 ± 9.5% of control). Co-treatment of
minocycline with bortezomib produced a significantly lower activation of astrocytes
versus saline-treated controls at day 30 (76 ± 3.0% of control), in contrast to the
astrocyte activation observed in rats treated with bortezomib alone. In short,
bortezomib-treated animals showed higher GFAP staining intensity at days7, 14,
and 30, with peak intensity at day 30.

Figure 8. GFAP staining intensity as represented in day 30 saline, bortezomib +
minocycline, and bortezomib-treated spinal cord tissue.
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3.3.4

Astrocyte Activation Following Oxaliplatin Treatment
Oxaliplatin-treated animals showed significantly higher GFAP fluorescence

intensity versus controls. Staining intensity for GFAP showed statistically significant
increases at day 7 (131 ± 9.4% of control) and day 14 (122 ± 4.7% of control) (Fig. 8
and Fig. 11B). Groups co-treated with minocycline showed an increase at day 7 (115
± 13.5% of control) and decrease at day 14 (91 ± 20.2% of control), but neither of
these findings were statistically significant. There was a decrease of GFAP intensity
versus control at day 40 (87 ± 7.8% of control), but this was not found to be
statistically significant. Because the increase in astrocyte activation from earlier time
points is fully reversed by this time, and because other studies have shown that
sensitivity to mechanical stimuli is abolished by this time, further time points were not
examined.

Figure 9. GFAP staining intensity as represented in day 7 dextrose, oxaliplatin
+ minocycline, and oxaliplatin-treated spinal cord tissue.

65

3.3.5

Astrocyte Activation Following Spinal Nerve Ligation
Astrocyte activation indicated by GFAP staining was significantly higher in

SNL rats on the ipsilateral side of the spinal cord versus the contralateral side (126 ±
9.28%) (Fig. 11C). Sham surgery rats showed no significant difference between
halves of the spinal cord ipsilateral or contralateral to surgery (100 ± 10.3%). The
overall finding was therefore in line with this model as a positive control, that there
was a marked activation of astrocytes only in those animals that received the actual
surgery, and this activation was significantly higher on the side ipsilateral to the
ligation.

3.3.6

Microglial Activation Following Spinal Nerve Ligation
Microglial expression of OX-42 was markedly higher in day 14 SNL rats

ipsilateral to surgery versus contralateral spinal cord (130 ± 12.3%), whereas sham
surgery rats showed statistically equivalent microglial expression on ipsilateral
versus contralateral spinal cord (98 ± 10.4%) (Fig. 9 and Fig. 11C). This was
therefore a trend in line with that of the SNL astrocyte data: the microglial activation
occurred only in SNL rats and primarily on the side of the spinal cord ipsilateral to
the ligation.
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3.3.7

Microglial Activation Following Bortezomib Treatment
The staining intensity of OX-42 as a marker for microglial activation was

slightly, though significantly, lower in bortezomib versus control at day 7 (95 ± 5.2%),
14 (96 ± 8.6%), and 30 (93 ± 4.6%) (Fig. 11D). The finding that bortezomib does not
activate microglia at any of the time points observed is in line with other models of
chemotherapy treatment.

67

Figure 10. OX-42 staining intensity in bortezomib and SNL. Staining is
increased following spinal nerve ligation (bottom) but not 30 days following
bortezomib treatment (top), or following sham surgery (middle). Inserts at show
increased magnification with background subtracted to highlight microglial cell
morphology in each condition.
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Figure 11. Glial marker expresion was quantified in bortezomib, oxaliplatin,
and SNL. Staining intensity in treated animals was expressed as a
percentage of intensity versus respective controls. (A) GFAP staining in
bortezomib-treated rats was significantly higher at days 7 (n=6 vs. n=5), 14
(n=7 vs. n=5), and 30 (n=6 vs. n=6), but not at day 69 (n=3 vs. n=3). Cotreatment with minocycline resulted in siginificantly lower GFAP staining at
day 30 (n=3). (B) GFAP staining in oxaliplatin-treated rats was significantly
higher at days 7 (n=9 vs. n=8) and 14 (n=9 vs. n=9), but not at day 40 (n=4
vs. n=4). Co-treatment with minocycline resulted in GFAP staining
equivalent to control at day 7 (n=6) and 14 (n=6). (C) Both GFAP and OX42 staining were higher in ipsilateral spinal cord in SNL rats (n=6) versus
contralateral cord. Neither GFAP nor OX-42 were higher in ipsilateral cord
in sham-treated rats (n=6) versus contralateral cord. (D) OX-42 staining
intensity in bortezomib-treated rats was significantly lower versus control at
days 7 (n=6 vs. n=5), 14 (n=7 vs. n=5), and 30 (n=8 vs. n=9).
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3.4.

DISCUSSION
The present study aimed to establish whether or not astrocytes play an active

role in oxaliplatin- or bortezomib-driven CIPN. The reported increases in GFAP were
indicative of this kind of trend, but it is uncertain what the downstream effects of this
activation may be. However, it is possible that astrocytes may have a bigger part in
pain as a whole than previously thought. One group recently reported that microglia
were not activated in a model of bone cancer pain (Ducourneau et al. 2014). It is
therefore possible that microglia are an important part of some, but not all, types of
pain. Astrocyte activation may be a far more universal form of reactive gliosis. It is
possible that the production of proinflammatory cytokines by astrocytes may
contribute to pain sensitization (Hald, 2009; Gao and Ji, 2010a; Bradesi, 2010). It is
well-known that excessive levels of these cytokines may result in sensitization of
neurons (Miller et al., 2009; Bradesi, 2010). The lack of a change in astroglial
activation in response to minocycline certainly seems to suggest that this activation
is mediated by inflammatory mechanisms. The case for proinflammatory cytokines is
further supported by the fact that minocycline has prevented their upregulation in
other models (Ledeboer et al., 2005; Mao-Ying et al., 2012). Many of the original
studies using minocycline to affect glia report effects on microglia without impacting
astrocytes (Yrjänheikki et al., 1999), but many other groups have reported that
minocycline exerts a robust effect on both types of glia (Ledeboer et al., 2005; Ryu
et al., 2004; Sung et al., 2012; Teng et al., 2004). These findings may very well
depend on that model is used, but the data of the present study suggest a
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mechanism for minocycline that does affect astrocytes. Co-treatment with both
bortezomib and minocycline was showed mechanical sensitivity and GFAP
expression resembling that of saline-treated controls. There was no concomitant
activation of microglia to suggest that minocycline was targeting these cells, rather
than astrocytes. Activation of either cell type may result in the production of
proinflammatory messengers, so this suggests that minocycline’s anti-inflammatory
activity is at work in the present model. Although tetracyclines like these are usually
classified as atibiotics, minocycline is usually prescribed for the treatment of
inflammatory acne (Garner et al., 2012). Its clinical use would therefore also suggest
a generalized anti-inflammatory mechanism. Additional research may benefit from
quantifying cytokines like IL-1β and TNF-α (Sung et al., 2012; Mao-Ying et al.,
2012). While these are largely expressed by microglia and neurons, these may also
appear in astrocytes and could be targets of interest for future study.
There are a number of directions that future research may take in order to
explain the apparently astrocyte-specific activation profile of the present study.
Firstly, it is possible that astrocytes possess specific receptors that respond to
extracellular damage or signals from outside the spinal cord altogether. Alternatively,
it is possible that propagation of this CIPN model depends on inter-astrocyte
signaling. Previous work has shown upregulation of astrocytic gap junctions
following oxaliplatin treatment (Yoon et al., 2013), but it is still unknown whether this
also occurs following treatment with other chemotherapeutic agents.
In addition to effects from cytokine expression, astrocytes may also contribute
to a maladaptive condition through regulation of glutamate transporters (Liaw et al.,
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2005; Cata et al., 2006a; Araque and Navarrete, 2010). Decreases in these
glutamate transporters have been reported in both injury and chemotherapy models
of neuropathy (Sung, Lim, and Mao, 2003; Weng et al., 2005; Cata et al., 2006a;
Xin, Weng, and Dougherty, 2009; Zhang, Xin, and Dougherty, 2009) and may
account for many of the maladaptive and pronounced symptoms that are reported
clinically (Cata et al., 2007; Dougherty et al., 2007; Boyette-Davis et al., 2013). The
persistent behaviors reported in the present study seem to suggest the possibility of
glutamate transporter dysfunction (Fig. 6B). Based on the time course and intensity
of glial activation and mechanical sensitivity, there is a strong possibility that the two
are correlated, but this has not been examined in the present study with regard to
other types of behavioral stimuli. Furthermore, other chemotherapy models have
shown decreases in peripheral nerve fibers in the skin, but it is unknown at this time
whether a similar effect is seen in bortezomib-treated animals. However, biopsies
taken from human patients have indicated that this may be the case. This effect was
likewise prevented by minocycline in animal models corresponding to other drugs. It
is certainly likely that the initial damage driving bortezomib-induced peripheral
neuropathy occurs outside of the spinal cord, but this warrants further study.
Understanding where the insults induced by bortezomib treatmen exert their primary
effects would be of particular interest in a clinical context in order to develop
treatments with maximal therapeutic efficacy. The Cavaletti lab has indicated
potential sites along the peripheral nerve upon which bortezomib may act, but there
are several issues with these studies that warrant follow-up research (see
introduction).
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Unlike bortezomib-treated rats, the animals treated with oxaliplatin did not
show a direct correlation in the time course of their mechanical sensitivity and
astroglial activation. Instead, the astrocytes in these animals were activated at
earlier time points, and activation decreased over time once treatment had ended.
This suggests differential mechanisms between the two. It may be that astrocytes
are activated in oxaliplatin-treated animals in an induction-dependent manner and
that they are activated in bortezomib-treated animals in a maintenance-dependent
manner. As with bortezomib-treated animals, however, oxaliplatin-treated animals
co-treated with minocycline showed behavior and glial activity resembling controls.
Microglial activation was not observed at any time point in either of the
chemotherapy models used in this study. The spinal nerve ligation animals used as
positive controls, on the other hand, developed a robust microgliosis, even at the
observed two-week time point. Many would argue that the microglia may still be
active at early time points, as there are reports suggesting that these cells are
responsible for the activation of astrocytes (Zhang et al., 2010). A follow-up
investigation was therefore conducted to help rule out this possibility (Appendix) In
conflict with our data, a recently-published study reported activation of microglia in
oxaliplatin-treated animals at day 7 (Di Cesare Mannelli et al., 2013). However, this
conflicts not only with the present data, but with earlier work that showed no
microgliosis in chemotherapy-treated animals in general (Zheng, Xiao, and Bennett,
2011). It should be noted that the conflicting study used a far greater dose of drug
than what was used in the present study, which may account for excess toxicity or
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damage that may have recruited microglia. On the other hand, this is the second
such study in which our group has reported no sign of microglial activation in a
chemotherapy model of neuropathy (Zhang et al., 2012). This is similar to the lack of
observed microgliosis in other cancer models (Ducourneau et al. 2014). There may
therefore be a common pathway for glial cell activation in these models, even though
they are markedly different.
Another possibility is that using the OX-42 antibody alone may not fully
characterize the activation of microglia. The use of the antibodies OX-42 and Iba1
has been well documented for the measure of overall activity and proliferation of
microglia. However, microglia also present with different activation states with
markedly different purposes. The M2 state is a quiescent, pro-survival state that aids
in maintaining neuronal health, but the M1 state is a reactive, inflammatory state that
may be detrimental to survival of neurons (Guerrero et al., 2012; Hu et al., 2012;
Boche, Perry, and Nicoll, 2013). There may be a possibility that microglia may shift
from one state to another without proliferating or recruiting other microglia. In such a
case as this, an antibody like OX-42 would not detect this kind of change. However,
the proliferative tendencies of microglia in neuropathic conditions are wellestablished.
Proinflammatory cytokines may indeed contribute to the CIPN state, but this
is generally thought of as primarily the territory of microglia (Ji and Suter, 2007;
Zhuang et al., 2007). For astrocytes to have this activity selectively, it may be
necessary to first identify some form of activation that is specific to astrocytes, such
as a receptor not found on microglia that triggers cytokine release. This should be
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taken into account when designing future studies. Furthermore, previous data in
other CIPN models suggests that the dysfunction of glutamate transporters is likely
to be found in the present model, as well (Zhang, Xin, and Dougherty, 2009; Nie,
Zhang, and Weng, 2010). At the very least, the present study has established that
the observed behavioral and astrocytic changes are related, and this has provided
ample direction for future research.
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4.

GLUTAMATE TRANSPORTERS AND CONNEXINS IN BIPN

4.1.

INTRODUCTION
The former two studies focused on establishing altered behaviors

corresponding neuronal function in the bortezomib CIPN model in rats and the
correlated changes in persistent behaviors and astrocyte activation, respectively.
From these two, it is possible to establish a correlation, but not a causal relationship.
The goal of the third study was then to investigate a possible means by which
astrocytes may directly contribute to BIPN. It is important to note that this is by no
means exhaustive. Furthermore, the course of a single study is sufficient to
strengthen this kind of case, but is not sufficient to conclusively determine how BIPN
is induced or maintained. Nevertheless, this study was designed to show whether
dysfunction of glutamate transporters and gap junctions in astrocytes occurs at the
time point corresponding to the peak of mechanical sensitivity. These were selected
as astrocyte-specific molecules which could contribute to changes observed in
behavior and neuronal function if disrupted. These changes had been previously
observed in other CIPN models, as well. The time point was selected in order to
match any changes to the behavioral and electrophysiological data previously
obtained. The hypothesis of this study was that increases in connexin 43 expression
and decreases in GLT-1 and GLAST expression correspond with behavioral
changes and astrocyte activation in the rat model of BIPN. The expression of
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connexin 43 verified this, but data from the expression of glutamate transporters
provided mixed results.
Bortezomib is a first-generation proteasome inhibitor chemotherapy drug
used primarily for the treatment of multiple myeloma. Among its multiple side effects,
bortezomib is known to produce chemotherapy-induced peripheral neuropathy
(CIPN) that may be dose-limiting (Argyriou et al., 2012; Ferrier et al., 2013; Argyriou
et al., 2014; Miltenburg and Boogerd, 2014). This neuropathy may extend long after
the cessation of treatment, and current treatment options to manage CIPN
symptoms are few and limited in their efficacy.
Among other forms of neuropathic pain, there is emerging evidence that
spinal astrocytes and microglia may contribute to the model’s development and
maintenance. However, it is becoming apparent that astrocytes are activated in the
absence of microglia in CIPN models. Our own lab has now demonstrated this in
paclitaxel, oxaliplatin, and bortezomib models of CIPN (Zhang et al., 2012;
Robinson, Zhang, and Dougherty, 2014a). However, there is currently limited
evidence demonstrating precisely how astrocytes may contribute to CIPN. Potential
candidate mechanisms have been identified, including the downregulation of
glutamate transporters in paclitaxel (Zhang et al., 2012) and the upregulation of
astrocytic gap junctions in oxaliplatin (Yoon et al., 2013). These provide promising
explanations for observed behavioral changes, but these findings had not yet been
replicated in other models of CIPN.
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The investigation of glutamate transporter dysfunction as a possible
mechanism for CIPN may be justified by observations of behavior and neuronal
activity in the spinal dorsal horn. Downregulation of glutamate transporters leads to
persistent synaptic glutamate, which is sufficient to potentiate action potentials, drive
persistent after-discharges, and even generate spontaneous ectopic activity (Matute,
Domercq, and Sánchez-Gómez, 2006; Yi and Hazell, 2006; López-Bayghen and
Ortega, 2011). Downregulation of glutamate transporters through pharmacological
means may even be sufficient to drive spontaneous nociceptive behaviors
(Nakagawa and Kaneko, 2010). Previous work from our lab has demonstrated
altered activity in spinal wide dynamic range neurons and downregulation of
glutamate transporters in support of such a model in animals treated with vincristine
or paclitaxel (Weng, Cordella, and Dougherty, 2003; Cata et al., 2006a). Work within
the bortezomib model has demonstrated behaviors indicating persistent sensation
and in vivo recordings showing potentiated responses and persistent afterdischarges in spinal wide dynamic range neurons (Robinson et al., 2014). Taken
together, it is possible that the changes observed in glutamate transporters in
paclitaxel may also carry over to the bortezomib model, as well.
The activity of connexin 43 is another point of interest in CIPN. Connexin 43
is the protein in astrocytes that composes gap junction hemichannels that connect
astrocytes together in a functional syncytium (Giaume and Liu, 2012; Theis and
Giaume, 2012). The openings that are formed by astrocytic gap junctions are small,
allowing only ions and molecules smaller than 1.2 kDa to pass. This is too small for
the majority of signaling molecules, but astrocytic gap junctions permit the flow of
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such messengers as calcium ions and glutamate between cells (Tabernero, Medina,
and Giaume, 2006; Theis and Giaume, 2012; Pannasch and Rouach, 2013).
Hemichannel-forming proteins are upregulated in conjunction with astrocyte
activation in multiple models of insult or injury, suggesting an increase in intercellular
communication in these reactive astrocytes (Homkajorn, Sims, and Muyderman,
2010; Chen et al., 2013; Chen et al., 2014). The potential downstream effects of this
increased hemichannel expression are of great interest in CIPN. Increases in
intracellular calcium in astrocytes may lead to decreased glutamate uptake or even
direct release of glutamate from astrocytes (Malarkey and Parpura, 2008; Devinsky
et al., 2013; Hansen and Malcangio, 2013; Aguirre et al., 2013). Thus, increases in
connexin 43 potentially indicate a parallel means by which astrocytes decrease
glutamate uptake at the tripartite synapse.
The focus of the present study is to assess the activity of the astrocytic
glutamate transporters GLT-1 and GLAST and the activity of connexin 43 in
bortezomib-treated animals. Data in support of previous findings in other models
would explain behaviors and electrophysiological data seen in bortezomib-treated
animals. The present work also includes minocycline in treatment groups, since this
has been shown to prevent behavioral changes in bortezomib-treated animals.
Therefore a direct role for connexins and glutamate transporters in bortezomibinduced peripheral neuropathy may only be established if (1) these proteins are
altered in accordance with an observed change of behavior, and (2) if prevention of
changes to behavior also prevent changes in these proteins. Carbenoxolone was
included in additional treatment groups for behavioral data as a gap junction
79

decoupler (Juszczak and Swiergiel, 2009; Yoon et al., 2013), and ceftriaxone was
included as an upregulator of glutamate transporter expression (Lee et al., 2008;
Kim et al., 2011). The inclusion of these treatment groups was to establish whether
pharmacological strategies to directly counteract possible changes would also
prevent the development of behavioral changes. Positive data would indicate that
changes to these proteins are sufficient to drive the bortezomib model of CIPN in
animals.
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4.2.

METHODS

4.2.1. Animals
All procedures were reviewed and approved by the M.D. Anderson
Institutional Animal Care and Use Committee and were in accordance with the
guidelines established by the NIH and the International Association for the Study of
Pain. 94 Male Sprague-Dawley rats between 60-75 days of age upon beginning
treatment (300-350 g) were used for all experiments. Of these rats, all 94 were used
for behavioral testing, but 21 of these were used for immunohistochemistry. Another
14 of these were used for Western blotting. Rats were housed in a facility with a 12h
light/dark cycle and were given food and water ad libitum. All efforts were taken at
each stage of the experiments to limit the numbers of animals used and any
discomfort to which they might be exposed.

4.2.2. Drugs
Saline, minocycline, and bortezomib were administered by intraperitoneal
injection, and volumes were calculated based on body mass to approximate a
volume of 0.5 ml. The gap junction decoupler ceftriaxone (Sigma Aldrich) and the
glutamate transporter upregulator carbenoxolone (Sigma Aldrich) were administered
intrathecally at a volume of 10μL. Animals were divided into eight treatment groups:
saline alone (n=11), saline + minocycline (n=11), saline + carbenoxolone (n=12),
saline + ceftriaxone (n=12), bortezomib alone (n=12), bortezomib + minocycline
(n=12), bortezomib + carbenoxolone (n=12), and bortezomib + ceftriaxone (n=12).
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Bortezomib (Millennium Pharmaceuticals) was administered in saline vehicle at a
dose of 0.15 mg/kg on days 1, 3, 5, and 7 of experimentation for a cumulative dose
of 0.60 mg/kg. Equivolume saline was administered to rats not treated with
bortezomib. Animals treated with minocycline hydrochloride (Sigma Aldrich) were
injected daily with 25.0 mg/kg minocycline in saline vehicle beginning at day 0 and
continuing daily through day 8 (one day past chemotherapy treatment) of
experimentation for a cumulative dose of 225mg/kg. Carbenoxolone (25μg/day) and
ceftriaxone (150μg/day) were administered on the same schedule as minocycline for
cumulative intrathecal doses of 225μg and 1350 μg, respectively. Animals not
injected with carbenoxolone or ceftriaxone were administered an equivalent volume
of saline intrathecally on the same dosing schedule.

4.2.3. Behavior Testing
Von Frey filament testing was used to assess mechanical sensitivity over time
as previously described (Boyette-Davis and Dougherty, 2011; Boyette-Davis et al.,
2011b; Robinson, Zhang, and Dougherty, 2014a). Briefly, filaments calibrated to a
bending force equal to 4g, 10g, 15g, and 26g were applied 6 times each to the midplantar surface of each hindpaw. Animals were allowed a half-hour to habituate to
the testing apparatus prior to application of filaments. Testing began with the lowest
(4g) filament and escalated in filament size until a withdrawal threshold was
reached. 5 to 10 minutes was allowed between filaments in order to minimize
responses due to anxiety or sensitization. Filaments were applied with steady force
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until bending of the filament was observed and held for approximately 1second.
Responses were classified as a rapid withdrawal of the paw immediately followed by
a return of the paw to the mesh. The threshold for sensitivity to mechanical stimuli
was recorded as the bending force of the filament for which at least 50% of
applications elicited a response. The mean was reported for each treatment group at
each time point. Error was reported as standard error of the mean (SEM), and
significance was tested at each time point using Mann-Whitney tests.

4.2.4. Tissue Collection
On day 30, following the final time point of behavioral testing, animals were
sacrificed for tissue collection. Rats were overdosed with sodium pentobarbital
(150mg), then perfused intracardially with room temperature heparinized saline,
followed by cold 4% paraformaldehyde in 0.1M phosphate buffer. After tissue
fixation was verified by rigidity of the rat’s extremities, spinal cords were removed
and post-fixed in 4% paraformaldehyde at 4oC overnight. Spinal cords were then
moved to 15% sucrose the following day, then moved after another 24h to 30%
sucrose for a minimum of 48h. The lumbar enlargement was mounted and the L5
segment cut in a cryostat at a thickness of 30μm.
For Western blotting, fresh tissue was collected from a different group of
animals. Animals were overdosed with sodium pentobarbital (150mg). Each animal
was then sacrificed via decapitation, and the spinal cord was quickly removed. The
dorsal horns of the spinal cord were taken and frozen rapidly using liquid nitrogen.
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All samples were then kept at -80°C until tissue could be processed. Following this,
tissue was homogenized in lysis buffer and centrifuged. The supernatant was taken
and had protein concentration quantified via Lowry assay. Protein concentration was
then adjusted to 1μg/μL for all samples and heated at 70°C for 10 minutes.

4.2.5

Immunohistochemistry
Spinal cord slices were washed in phosphate buffered saline (PBS) for 6

washes lasting 15 minutes each and then blocked in normal donkey serum (5% NDS
and 0.2% triton X in PBS). Slices were incubated overnight at 4oC with primary
antibodies against GFAP (mouse anti-rat 1:1000, Cell Signaling Technology),
connexin 43 (rabbit anti-rat 1:1000, Invitrogen), GLT-1 (guinea pig anti-rat 1:2000,
Chemicon), or GLAST (rabbit anti-rat 1:250, Abcam). Slices were washed the
following day in PBS for 6 washes lasting 15 minutes each, then incubated with
secondary antibodies. For one set of tissue, slices were incubated with FITCconjugated donkey anti-mouse secondary antibody for GFAP detection (1:500,
Jackson Immunoresearch) and Cy-3-conjugated donkey anti-rabbit secondary
antibody for Cx43 detection (1:500, Jackson Immunoresearch). A second set of
tissue was incubated with FITC-conjugated donkey anti-guinea pig secondary
antibody for GLT-1 detection (1:500, Jackson Immunoresearch) and Cy-3conjugated donkey anti-rabbit secondary antibody for GLAST detection (1:500,
Jackson Immunoresearch). All tissue was incubated with secondary antibodies for 2
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hours at room temperature. Slices were washed for a final course of 6 washes
lasting 15 minutes each, then mounted onto glass slides using Vectamount medium.

4.2.6. Quantification of Immunohistochemistry
Slices were viewed and images captured using fluorescent illumination at 20X
magnification using a Nikon Eclipse E600 microscope. Captured images were
analyzed using NIS Elements software (Nikon, USA). A region of interest was drawn
within the dorsal horn containing lamina I and II for quantification purposes. A region
outside of the tissue slice was selected as background, and its signal was subtracted
from the entire image. The signal within the dorsal horn region of interest was then
expressed as intensity in pixels/μm2. For each treatment group, the mean of these
values was calculated and expressed as a percent versus the mean values of the
saline-treated group. Error was expressed as the combined standard error of the
mean (SEM) for the corresponding treatment and saline-treated groups to account
for variability within controls. Significance was determined via t-test (P = 0.05, 0.01).

4.2.7. Western Blotting
For each Western blot, 20μL of each sample (20μg protein) was separated
via gel electrophoresis and transferred to polyvynilidene (PVDF) membranes. After
transferring, membranes were washed three times for 10 minutes each in Trisbuffered saline with Tween-20 (TBST). Membranes were then blocked in a solution
of 5% powdered nonfat milk in TBST for 1 hour at room temperature. Primary
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antibodies were added, and membranes were incubated overnight at 4°C. The
membranes were then washed three times for 10 minutes each in TBST. These
were then incubated with secondary antibodies conjugated against horseradish
protein (HRP) in 5% nonfat milk/TBST solution for 30 minutes at room temperature
and washed a final three times at 10 minutes each in TBST. Target proteins on
membranes were then visualized using an enhanced chemiluminescence system
(Amersham Pharmacia Biotech, Little Chalfont, UK). Primary antibodies were
selected in order to verify changes observed in immunohistochemistry. The primary
antibodies used for Western blotting were the same as those used for
immunohistochemistry, incubated at a 1:1000 concentration. Mouse anti-rat betaactin (1:10,000, Sigma) was also included as a control for basal protein expression.
Secondary antibodies were either goat anti-rabbit or goat anti-mouse HRPconjugated antibodies (1:10,000, Calbiochem).
Band intensity was quantified using ImageJ software, available from the NIH
website. A region of interest containing the full band was taken, and background was
subtracted. The expression of a protein was then quantified as the ratio of the
expression of that protein over the expression of beta-actin in the same lane. The
average of these values was taken for saline treated controls. The other treatment
groups were then normalized as a percentage of this value. Error bars were
calculated as the SEM, and significance was determined via t-test (p = 0.05, 0.01).
For the connexin 43 antibody, which detects three bands for different
phosphorylation states, this calculation was performed for total amount of connexin
43 and for each phosphorylation state.
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4.3.

RESULTS

4.3.1. Mechanical Withdrawal Thresholds
Mean withdrawal thresholds across groups were not significantly different at
baseline (Fig. 12). Animals treated with saline alone or saline with minocycline,
carbenoxolone, or ceftriaxone (not shown) did not change over time versus baseline
withdrawal threshold. Bortezomib-treated animals first showed a significant
difference in withdrawal thresholds versus saline-treated controls at day 14 (19.5 ±
1.9g saline/ 11.2 ± 0.9g bortezomib). Thresholds continued to decrease and showed
significant differences at day 21 (18.1 ± 2.4g saline/ 6.5 ± 0.9g bortezomib) and day
28 (20.6 ± 2.1g saline/ 7.1 ± 1.2g bortezomib). Animals co-treatmed with
minocycline, ceftriaxone, or carbenoxolone did not differ significantly from salinetreated controls at any time point that was tested.
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Figure 12. Mechanical sensitivity was assessed in bortezomib-treated
animals versus preventative treatment groups. Treatment of animals with
bortezomib (n=12) induced mechanical hypersensitivity versus salinetreated controls (n=11) that was not observed in rats co-treated with
minocycline (n=12), carbenoxolone (n=12), or ceftriaxone (n=12). Rats
treated with minocycline (n=11), carbenoxolone (n=12), or ceftriaxone
(n=12) alone did not develop mechanical hypersensitivity (not shown).
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4.3.2. Astrocyte Activation
GFAP staining for astrocytes showed no difference in minocycline-treated rats
versus saline-treated controls (104.9 ± 13.6% of control) (Fig. 13). Astrocytes from
these groups showed thin arbors and uniform distribution throughout the dorsal horn
gray matter (top-left and bottom-left panels). Bortezomib-treated rats showed
significantly higher GFAP activation versus controls (132.1 ± 16.9% of control).
Astrocytes from this group showed brighter staining, hypertrophy, and increased
arborization (top-right panel). Distribution of astrocytes was uniform throughout the
dorsal horn in this group, as well. Minocycline co-treatment animals were not
significantly different from controls (113.1 ± 16.2% of control). Qualitative
observations of cell size, brightness, arborization, and distribution indicated no
apparent difference in the astrocytes in this tissue versus saline-treated controls
(bottom-right panel). These findings are in line with previous data from our lab
showing the same profile of activation (Robinson, Zhang, and Dougherty, 2014a).
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GFAP Expression

Figure 13. Activation of GFAP was expressed as percent fluorescence
intensity versus mean fluorescence intensity of control. Treatment of
animals with bortezomib (n=5) induced a significantly increased expression
of GFAP in astrocytes versus saline-treated controls (n=6). Animals cotreated with minocycline (n=5) did not differ from saline-treated controls.
Minocyline alone (n=5) did not affect GFAP activity.
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4.3.3. Connexin 43 Expression
Staining for connexin 43 activation was equivalent in minocycline-treated rats
versus saline-treated controls (97.3 ± 17.6% of control) (Fig. 14). Connexin 43
staining was distributed evenly throughout the dorsal horn (top-left and bottom-left
panels). The staining was granular in appearance, indicating staining of gap
junctions apart from background levels of staining. Bortezomib-treated rats showed
a significant upregulation of connexin 43 expression (131.3 ± 19.3% of control). The
dorsal horn staining appeared brighter in this tissue than in saline-treated controls
(top-right panel). This could indicate either increases in the brightness of individual
gap junctions or an increase in the number of gap junctions. Rats that were also
treated with minocycline did not differ from controls (111.7 ± 19.9% of control).
Levels of connexin 43 in these animals were higher than in saline-treated controls,
but the difference was not significant (bottom-right panel). Staining was slightly
brighter in this tissue than in saline-treated controls, but it maintained an even
distribution and granular appearance. This would indicate a significant abrogation by
minocycline of the connexin increases induced by bortezomib.
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Connexin 43 Expression

Figure 14. Expression of connexin 43 was represented as percent
fluorescence intensity versus mean fluorescence intensity of control.
Treatment of animals with bortezomib (n=5) induced a significantly
increased expression of connexin 43 in the spinal dorsal horn versus
saline-treated controls (n=6) Animals co-treated with minocycline (n=5) did
not differ from saline-treated controls. Minocyline alone (n=5) did not affect
connexin 43 activity.
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4.3.4. GLT-1 Expression
Staining for GLT-1 activation did not differ significantly between minocyclinetreated and saline-treated groups (111.7 ± 8.1% of control) (Fig. 15). There was also
no change detected in rats treated with bortezomib (102.9 ± 10.5% of control) or
bortezomib and minocycline (98.4 ± 12.3% of control). GLT-1 staining was not
localized to any one region of the spinal cord gray matter. There was minimal
staining within the white matter, which reflects the paucity of synapses in these
regions. Furthermore, staining was granular in appearance, but difficult to distinguish
in appearance from background staining. The difficulty in distinguishing background
from signal could potentially mask smaller changes, but the current data did not
indicate any difference between treatment groups with this staining.
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GLT-1 Expression

Figure 15. Expression of GLT-1 was represented as percent fluorescence
intensity versus mean fluorescence intensity of control. Treatment of
animals with bortezomib (n=5), minocycline alone (n=5), or bortezomib +
minocycline (n=5) showed no change in GLT-1 expression in the spinal
dorsal horn versus saline-treated controls (n=6).
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4.3.5. GLAST Expression
Expression of GLAST was not significantly different in minocycline-treated
rats versus saline-treated rats (106.7 ± 10.5% of control) (Fig. 16). Staining was
most densely localized to the first two laminae of the dorsal horn, which is where
nociceptive neurons synapse (top-left and bottom-left panels). Staining was granular
in appearance. Bortezomib-treated rats showed significantly lower expression of
GLAST (81.5 ± 8.5% of control), as did animals co-treated with minocycline,
although to a lesser extent (top-right and bottom-right panels). However, there did
not appear to be analogous differences in staining in regions outside of the
quantified region. It is difficult to say whether this is truly the case, considering that
the far greater brightness in the first two laminae could overshadow lesser changes.
Animals treated with both bortezomib and minocycline still showed significantly lower
expression of GLAST versus saline-treated animals (87.0 ± 7.9% of control),
although this change showed a lower degree of significance versus animals treated
with bortezomib alone.
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GLAST Expression

Figure 16. Expression of GLAST was represented as percent fluorescence
intensity versus mean fluorescence intensity of control. Treatment of
animals with bortezomib (n=5) significantly decreased expression of
GLAST in the spinal dorsal horn versus saline-treated controls (n=6).
Animals co-treated with minocycline (n=5) differed from saline-treated
controls, but decrease of GLAST was not as pronounced. Minocyline alone
(n=5) did not affect GLAST activity.
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4.3.6. Western Blotting
Western blotting data for the GLAST antibody yielded no significant
differences between any of the treatment groups (Fig. 17). Tissue from animals
treated with minocycline alone showed slightly lower staining than saline-treated
animals, but these differences were not significant. However, connexin 43
expression showed significant changes in the expression of its different
phosphorylation states (Fig. 18). The different bands detected by the connexin 43
antibody corresponded to non-phosphorylated (NP), phosphorylated (P1), and
phosphorylated (P2) forms of connexin 43. There was no significant difference
between groups in the NP bands or the P2 bands. There was, however, a
significantly higher expression of phosphorylated (P1) connexin 43 in both the
groups treated with bortezomib alone (494.7 ± 103.7% of control) and those treated
with both bortezomib and minocycline (308.0 ± 85.3% of control). The antibody used
was for the detection of overall connexin 43 expression, rather than phosphorylated
connexin 43 selectively. It is therefore unlikely that the observed effects are a result
of preferential staining of one state over another. The tissue corresponding to
bortezomib-treated animals also appeared to have greater overall staining, but this
was not compared quantitatively.
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Figure 17. Western blotting data for GLAST did not indicate significant
differences between treatment groups. Treatment groups included saline (n=4),
minocycline (n=4), bortezomib (n=4), and bortezomib + minocycline (n=4).
Ratios for each band were calculated as GLAST intensity over beta-actin
intensity within the same lane. Band intensity was expressed as a percent
increase of the average ratio for a treatment group versus the average ratio of
saline-treated controls.
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Figure 18. Western blotting data for connexin 43 indicated significant differences
between treatment groups. Treatment groups included saline (n=3), minocycline
(n=4), bortezomib (n=3), and bortezomib + minocycline (n=4). Bands for individual
phosphorylation states indicated an increase in the P1 phosphorylation state of
connexin 43 in animals treated with bortezomib or bortezomib + minocycline. Ratios
for each band were calculated as connexin 43 intensity over beta-actin intensity
within the same lane. Band intensity was expressed as a percent increase of the
average ratio for a treatment group versus the average ratio of saline-treated
controls.
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4.4.

DISCUSSION
The data in the present study show alterations in astrocytic connexins and

glutamate transporters in animals treated with bortezomib. Previous work in our lab
has shown a clear involvement of astrocytes in various forms of CIPN, and these
changes provide a possible means by which astrocytes may contribute to these
models. First, GFAP staining and von Frey mechanical sensitivity were used to verify
the bortezomib-induced behavioral changes. Development of mechanical
hypersensitivity and astrocyte activation were in line with previous data from our lab
(Robinson, Zhang, and Dougherty, 2014a; Robinson, Zhang, and Dougherty,
2014b).
For immunohistochemistry, the 30-day time point in this model was selected
because it corresponds to peak behavioral sensitivity. In addition to the activation of
GFAP, increased expression of connexin 43 was observed. The changes in the
levels of these two markers were nearly identical. This increase in connexin 43
expression suggests possible increased flow of calcium ions between astrocytes that
may result in glutamate release. A possible point of interest for future
experimentation would be to verify whether this glutamate release occurs in vitro.
Alternatively, in vivo electrophysiology in rats treated with gap junction decouplers
like carbenoxolone could be employed to see whether this inhibition of connexin 43
prevents potentiated responses to stimuli. However, it is possible that the connexins
are responsible for the transport of other intercellular signal molecules. What exactly
they may contribute in the context of this model is currently unknown, but the data in
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the present study show a clear correlation between peak hyperalgesia and connexin
activity.
The involvement of glutamate transporters in the present study was less
clear-cut than that of connexin 43. While GLAST was downregulated in the
immunohistochemistry data in this model, no change was observed in GLT-1
expression. It is unknown why one form of astrocytic glutamate transporter would be
depressed without another. However, the decreased levels of at least one form of
glutamate transporter at the peak of the behavioral changes suggests a mechanism
for persistent sensations and persistent after-discharges observed in other studies
from our lab (Robinson, Zhang, and Dougherty, 2014a; Robinson, Zhang, and
Dougherty, 2014b). One possibility for the disparity between GLT-1 and GLAST is
that GLT-1 activity may be involved at a different time point. The possibility of early
and late forms of glutamate transporter downregulation has not been explored to the
knowledge of the author, but another study from our lab has shown GLT-1 and
GLAST downregulation at earlier time points that returns to baseline at later time
points (Zhang et al., 2012). The successful use of ceftriaxone, which is generally
considered to be specific to GLT-1 upregulation (Lee et al., 2008), would suggest
that early GLT-1 changes are a strong possibility. It is therefore possible that a
follow-up study examining earlier time points in bortezomib-treated rats would yield a
similar result of early downregulation of GLT-1. The early downregulation of
glutamate transporters would then suggest the induction of central sensitization that
persists long after the changed expression resolves.

101

The Western blotting data both validated and contradicted the changes
observed in immunohistochemistry. The lack of any change observed in GLAST is
difficult to explain, but it is possible that the means of processing the tissue for
Western blotting washed out any changes that may have occurred. Considering that
the change in expression observed in immunohistochemistry was less than 20% and
surveyed only in the first two laminae of the dorsal horn within the gray matter, it is
possible that inclusion of the entire dorsal half of the spinal cord for Western blotting
diluted any changes that may have occurred in a much smaller region.
The changes observed in connexin 43 Western blotting, on the other hand,
were of particular interest. There was a clear shift in phosphorylation of connexin 43
in bortezomib-treated animals. The P1 phosphorylation state of connexin 43
corresponds to increased trafficking of connexin 43 from the cytoplasm to the
membrane (Solan and Lampe, 2007). This would indicate that there is not only an
apparent increase in overall expression of the protein, but that it is also being
transported for use within a greater number of gap junctions, as well.
The activity of minocycline co-treatment in the present study showed more
similarity to controls versus the changes induced by bortezomib. Behavior, GFAP
expression, and connexin 43 expression did not differ significantly from controls, and
the changes observed in GLAST were not as significant as the changes observed in
animals treated with bortezomib alone. Furthermore, the phosphorylation states of
connexin 43 in animals treated with both bortezomib and minocycline indicate that
minocycline exerted its effects on connexin 43 activity by affecting the increase in
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expression, rather than by altering its post-translational modification. This suggests
that minocycline acts on a target upstream of the regulation of connexin 43.
The behavioral data obtained from animals co-treated with carbenoxolone or
ceftriaxone showed that these animals did not differ in behavior from saline-treated
controls. Further studies using these three agents may provide important information
on the mechanisms of CIPN as well as potential therapeutic strategies for its
prevention.
Previous studies from our lab have clearly demonstrated a correlation
between astrocytes and animal models of CIPN. The changes to connexin and
glutamate transporter expression observed now in bortezomib-treated animals
provide mechanistic support for direct astrocytic involvement. In conjunction with
similar studies in oxaliplatin and paclitaxel, there is increasing evidence for a unified
pathway for the development of CIPN. However, upstream mechanisms for
astrocyte activation are not well understood. A recent study from our lab in
paclitaxel-treated rats has demonstrated increases in TLR4 and MyD88 in DRG and
TLR4 in spinal cord (Li et al., 2014). This suggests that damage-associated
molecular patterns from outside of the spinal cord may activate astrocytes. It also
strongly suggests increases in proinflammatory cytokines released from astrocytes.
This could have a direct impact on glutamate transporter expression, and it could
further sensitize surrounding neurons to glutamate signaling directly. Furthermore,
TLR4 activation is capable of upregulating connexin 43 (Aguirre et al., 2013), which
strongly suggests a possible single site for all of the activity observed in gap
junction, glutamate transporter, and cytokine regulation. However, whether or not
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TLR4 is activated by chemotherapy treatment as a whole has yet to be verified
outside of the paclitaxel model. Future studies should be conducted to verify whether
this occurs in the bortezomib model, as well. The activity of astrocytes provides a
very promising point for studies to elaborate on an overall pathway for CIPN, as well
as for the development of therapeutic strategies for its prevention.
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5.

CONCLUSION

5.1.

General Conclusions
The research encompassed by this dissertation was geared towards an

understanding of one possible means by which bortezomib may cause
chemotherapy-induced peripheral neuropathy. To provide a true answer to this
question is far beyond the scope of what is attainable in a single dissertation, but the
present work was sufficient to set a basic framework for future study. Prior research
was sufficient to establish a possible link between astrocytes and CIPN in paclitaxel,
but these observations had not been generalized to other drugs.
Because of the lack of previous research published on BIPN in animals, it
was important to first characterize what behavioral modalities are affected within the
rat model and how neuronal responses in the spinal cord may be altered. Without
this first step, it would have otherwise been impossible to tie any mechanistic studies
back to the overall presentation of BIPN in rats. The summarized findings of this
initial study were that sensitivity to mechanical stimuli was increased in bortezomibtreated animals without affecting heat or cold sensation or motor capability, and
bortezomib-treated animals showed persistent withdrawal behaviors that paralleled
increased activity and persistent after-discharges in spinal wide dynamic range
neurons. These findings were distinct from the trend seen in patients, which includes
sensitivity to cold stimuli, as well as behaviors seen in other models of CIPN.
However, the activity of spinal WDR neurons was in line with previous findings and
provided a case for disrupted glutamate transport. Although the stimulus application
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in this data was not blind, the activity of neurons in response to venous clip or
arterial clip, which are free of observer input, nevertheless provided objective
measures of increased and persistent WDR neuron firing.
The second major point of study followed on previous findings within our lab
that demonstrated activation of astrocytes in paclitaxel in the absence of microglial
activation. In this study, the same general activation profile was found in animals
treated with bortezomib or oxaliplatin. The time course of this activation varies from
one drug to another, but this study showed a generalized correlation between CIPN
and activation of astrocytes. Furthermore, this study demonstrated that behaviors
and expression of observed proteins in animals co-treated with minocycline either
did not differ from saline-treated controls or showed less of a change than those
treated with bortezomib alone. This strongly suggested that proinflammatory signals
drive both the behavior and glial activity. Nevertheless, this was not sufficient to
establish a causal relationship.
The final study sought to establish a means by which astrocytes may directly
contribute to BIPN through mechanisms specific to these cells. The activation profile
of connexins and glutamate transporters in this study revealed that connexin 43 and
GLAST were affected at the time point corresponding to peak behavioral sensitivity.
This evidence favors a glial mechanism for BIPN, as the disruption of glutamate
transport and increases in inter-astrocyte signaling could explain enhanced and
persistent responses at the behavioral level. This still does not exhaust every
possibility for a role for astrocytes, and it does not conclusively explain what
happens downstream from connexin upregulation. However, this study established a
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high likelihood that the simultaneous changes in behavior and glial activation are
directly related.
The findings of these studies support a model of astrocyte involvement in an
animal model of BIPN. The observed activation is present in every instance of the
disorder, it is not present in the absence of the disorder, and suppression of this
change coincides with the suppression of the disorder. However, future studies
should focus on establishing upstream and downstream targets to clarify more
exactly the role of astrocytes in BIPN. The present studies have not included a
survey of proinflammatory cytokines and chemokines induced by BIPN, in spite of
the clear activity of minocycline in affecting how bortezomib impacts behavioral and
glial changes. However, because of the diverse activity of proinflammatory cytokines
and chemokines that may be induced by activation of astrocytes, this could be the
subject of a dissertation on its own. Among the possible activities related to
proinflammatory messengers, it is possible that their release from astrocytes would
be sufficient to lower response thresholds in neurons and drive central sensitization.
In combination with the present findings regarding glutamate transport and
connexins, such a finding could explain a mechanism by which astrocyte activation
contributes to BIPN.
From a therapeutic perspective, it would be extremely important for future
studies to investigate the upstream components that are responsible for astrocyte
activation. The inability of bortezomib to cross the blood-brain barrier clearly
indicates that BIPN begins in the periphery. It is therefore important to investigate
how peripheral nerve fibers and dorsal root ganglia may be affected by bortezomib
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so that therapeutic strategies may target BIPN at its root. Findings in paclitaxel that
heat shock proteins are activated in spinal astrocytes (Li et al., 2014) need to be
investigated in bortezomib-treated rats, as well. A translation of these findings to the
bortezomib model would suggest a means by which astrocytes may be activated.
Heat shock proteins such as HSP90 respond to a diverse array of both pathogenassociated molecular patterns (PAMPs) and damage-associated molecular patterns
(DAMPs) (Harris, Andersson, and Pisetsky, 2012; Zhao et al., 2014). In particular,
DAMPs like high mobility group box 1 (HMGB1) are released following cellular stress
or damage (Harris, Andersson, and Pisetsky, 2012; Keyel 2014). Therefore, if
damage at the level of the dorsal root ganglion occurs in response to bortezomib
treatment, it is possible that release of HMGB1 could activate astrocytes and
potentiate neuronal responses in the dorsal root ganglion. However, this requires
extensive investigation in order to be anything more than conjecture and is only one
possibility. If the findings related to heat shock proteins in paclitaxel are replicated in
bortezomib, then it is possible that a pathway like this one could be at the heart of
CIPN as a whole.
In addition to establishing a preclinical model of BIPN, the findings in the
present studies must also be translated into clinical studies in order to be effective.
While the astrocytes cannot be surveyed directly in living patients, the present
studies have provided potential molecular targets and therapeutic agents for
investigation in clinical trial. In particular, minocycline has shown great promise. Our
lab has been in collaboration with other investigators previously to investigate the
effects of minocycline in bortezomib-treated patients, but these efforts were
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inconclusive. This trial therefore needs repetition in order to ascertain whether or not
minocycline is effective in patients, as well. Even if it is not, there may be other,
more specific drugs that may prove to be effective. However, minocycline is already
well-established and safe, and it is therefore also desirable from a standpoint of FDA
approval. Additional studies will also be necessary to ensure that any possible
treatments for the prevention of BIPN do not negatively impact the efficacy of
bortezomib as an anti-tumor agent.
The present studies show promise for identifying a cause for bortezomibinduced peripheral neuropathy, as well as potentially chemotherapy-induced
peripheral neuropathy as a whole or other neuropathies altogether. It is clear that
astrocytes are more intimately involved in such disorders than previously thought,
and it is possible that the impact of this work may have ramifications that bleed over
into other areas of research in the future.

5.2.

Shortcomings of the Animal BIPN Model
The findings of this dissertation have provided several promising targets for

future study in characterizing BIPN. However, there are several points at which the
animal model does not fully match what is seen in patients. The first of these to
address is that the rats used in modeling BIPN do not have cancer. It is entirely
possible that some BIPN symptoms in patients may be affected by changes resulting
from multiple myeloma in a currently unknown manner. However, the neuropathy as
induced by bortezomib itself was the focus of this research, and cancer was not
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modeled in the interest of observing the effects of bortezomib isolated from other
influences. Second, the dosage used in the current research was equivalent to a
single cycle of bortezomib treatment, whereas patients receive multiple cycles of
treatment. A dose was selected for rats based on what would induce altered
behavioral symptoms without excessive cytotoxicity as a possible confound, and so
this dosing schedule was selected. This then identifies another possible confound, in
that patients were reported in the introduction to be most likely to develop symptoms
between three to five cycles of treatment, whereas a single ―cycle‖ in rats was
sufficient to induce behavioral changes. However, it was also noted that a single
cycle may in some cases be sufficient for patients to develop CIPN symptoms, so it
is possible for animals to show a similar predisposition. Also, 37% of patients were
reported to develop BIPN, whereas the animals used uniformly developed
behavioral changes when treated with bortezomib. With the Sprague-Dawley strain
of lab rats used, there is a high degree of homogeneity among individuals due to
large-scale inbreeding, so it is possible that both a predisposition to earlier onset of
symptoms and uniformity of symptom development could occur in a set of
individuals with uniform genes. Even so, there is little data surrounding what genetic
markers may predispose individuals to BIPN, so this cannot be proven either way.
In addition to issues concerning dosing schedules and symptom onset, there
is also an issue in the nature of symptoms developed. Patients are scored based on
paresthesias in most neuropathy scores, although painful symptoms are also
common (Berkowitz and Walker, 2012). These painful symptoms are of greater
concern than non-painful symptoms and are more likely to necessitate dose
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reduction. Symptoms in patients may also include numbness or lack of sensation in
BIPN. On the other hand, rats developed behaviors that are frequently interpreted by
investigators as painful and increased, rather than decreased, sensitivity to stimuli.
One explanation for why loss of sensation is not observed in animals could be a
function of the lower dose used. If the Cavaletti lab is correct in reporting that
peripheral nerve damage and axonal degeneration is the initial cause of BIPN, then
damage could cause spontaneous or enhanced sensations, and a subsequent
complete denervation could then result in loss of sensation. It is therefore possible
that the lower dose used in the current model is not sufficient to generate this kind of
effect. As for the distinction between painful symptoms and non-painful
paresthesias, this is one drawback of using reflexive measures. It is impossible to
distinguish between responses to either of these types of stimuli using the present
methods. A reflexive withdrawal could indicate either a nocifensive response or
increased vigilance to stimuli in response to unpleasant paresthesias. However,
either of these sensations would indicate neuropathy in the animal model. Care must
therefore be taken that conclusions derived from this model are not dependent on
behaviors occurring in response to pain.
Another possible contributing factor to the disparity between patient
symptoms and the animal model is the presence of comorbidities and differences in
patient demographics. The presence of diabetes is notable among multiple myeloma
patients observed within our own clinical data, and it is possible that sub-clinical
diabetic neuropathy is present in many of these individuals prior to treatment. This is
not the only possible contributor to neuropathy, but is by far the most prevalent.
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Furthermore, multiple myeloma patients are generally at least middle-aged, if not
older. The rats used in the dissertation research were adolescents. It is possible that
the disparity in age could account for part of the mismatch in symptom severity,
recovery time, or other differences in observed symptoms. Many patients receiving
chemotherapy treatment have also had prior or overlapping radiation treatment that
may have a further negative effect on nerve function. It would be an important followup study to model comorbidities of diabetes with streptozotocin or radiation
treatment by irradiating animals in order to determine if either of these may
contribute. Using elderly rats in experiments may also be beneficial.
The fact that affected behaviors in animals were isolated to mechanical
stimulation also warrants further discussion. It is possible that there is a subtype of
sensory neurons preferentially affected by bortezomib that have a lesser response to
thermal stimuli. For example, while IB4+ sensory neurons may still respond to heat
stimuli, IB4- sensory neurons respond to heat to a much greater extent (Stucky and
Lewin, 1999). It is unknown, however, how or why cells like these would be
selectively targeted in rats and not humans. Furthermore, patients show a decrease
in motor skill that was not seen in rats (Cata et al., 2007). This may be due in part to
the disparity between type of motor skills tested. Whereas patients displayed marked
decreases in fine motor skill, rats were tested on coordinated walking ability. There
is not a test in the animal model that would directly parallel pegboard completion, so
the rotarod was selected on the basis of testing overall motor capability. It is possible
that rats also exhibit impaired fine motor skill, but that the current testing methods
were not sufficient to detect such a change.
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5.3.

Proposed Molecular Pathway of the BIPN Animal Model
The research of this dissertation has been limited to several preliminary

studies aimed at a general mechanistic framework. There is substantial room for
future studies to further investigate the molecular pathway that may be responsible
for BIPN based on the findings in other animal models of neuropathy. From these
findings, it is possible to extrapolate a hypothetical pathway that ties together current
findings in the animal model of BIPN from our lab and others. One such pathway will
be outlined in this section and summarized in Fig. 19.
The primary basis of Cavaletti’s work in BIPN centers around damage to
peripheral nerves. The hypothesis is certainly justified, since bortezomib does not
cross the blood-brain barrier. Cavaletti has presented data indicating possible axonal
degeneration (Carozzi et al., 2013) and the involvement of damage-associated
molecules such as TNF-α, CGRP, and substance P in the dorsal root ganglion
(Chiorazzi et al., 2013; Quartu et al., 2014). Satellite glial cells may further contribute
to this, as spontaneous discharges that may be induced by axonal degeneration
cause release of ATP and MMP9 from DRG neurons that triggers the release of
TNF-α and IL-1β from satellite glial cells (Ji, Berta, and Nedergaard, 2013).
Although Cavaletti has not investigated the activity of high-mobility group box
1 (HMGB1) in bortezomib, this is a damage-associated molecular pattern (DAMP)
that could also be involved in a maladaptive signal from the DRG. It is not the only
possibility for DAMP expression in the DRG, but is of particular interest because of
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its relationship to TNF-α and activity on astrocytes. The activity of TNF-α has shown
to be necessary for the expression of HMGB1 in DRG in a CCI model of neuropathy
(Wang et al., 2013), and application of TNF-α has even been shown to induce
secretion of HMGB1 in some cell types (Willenbrock et al., 2012). It is unknown at
this time whether DAMPs like HMGB1 may be released from the DRG into the spinal
cord, but this is one means by which downstream activity could potentially be
induced. In favor of this possibility, an SNL model was shown to induce expression
of HMGB1 and one of its receptors, the receptor for advanced glycation end
products (RAGE), in both DRG and spinal cord (Shibasaki et al., 2010). The
expression of these molecules was lower in the spinal cord than in the DRG, but this
suggests some kind of communication in HMGB1 and RAGE expression from the
DRG into the spinal cord, although how this occurs is unknown. Furthermore,
expression of RAGE was limited to the spinal dorsal horn, suggesting a potential role
in altered somatosensation.
RAGE is implicated in the activity of toll-like receptors, particularly in
potentiating the activity of TLR4. Although TLR4 is often attributed to microglial
activity, it is important to note that TLR4, RAGE, and HMGB1 expression are all
simultaneously increased in spinal cord astrocytes in models like ALS (Casula et al.,
2011). The downstream activity of astrocytic toll-like receptors is then sufficient to
explain a variety of the findings of this dissertation. Astrocytic TLR4 activates the
MAPK pathways for p38, ERK, and JNK (Liu, Gao, and Ji, 2012), each of which
have a possible contributing role to the BIPN model.
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The activity of p38 has recently been shown to be necessary for increases of
GFAP expression that were used to indicate reactive gliosis (Roy Choudhury et al.,
2014). GFAP was selected as a structural marker for its historical use and positive
correlation with neuropathy models, but also because there are at this time no
known functional markers consistently indicative of reactive astrocytosis (Watkins
and Maier, 2003; Cao and Zhang, 2008). GFAP is a protein that composes
intermediate filaments in astrocytes that are responsible for a multitude of purposes,
including the trafficking of GLAST (Middeldorp and Hol, 2011), and GFAP
expression has been shown to be inversely proportional to GLAST expression in
neuropathy models (Xin, Weng, and Dougherty, 2009; Gao and Ji, 2010b), but it is
unlikely that it has a direct contribution to neuropathy (Watkins and Maier, 2003).
However, these changes do occur in parallel to other functional changes proposed.
The p38 pathway has also been shown to induce expression of connexin 43,
the major astrocytic gap junction protein (Morioka et al., 2014). Along with glutamate
transporters, gap junctions may contribute to persistent synaptic glutamate through
increases in astrocyte intracellular calcium, which triggers glutamate release from
astrocytes. The data of this dissertation has indicated a possible role for Cx43 and
GLAST in this model, lending credence to the possibility of persistent synaptic
glutamate. GLAST expression may be decreased by activation of TLR3 (Costello
and Lynch, 2013). Although it has not been investigated in the context of TLR4,
decreases in GLAST expression coincide with increased phosphorylation of ERK,
which is common to both TLR3 and TLR4 (Zamoner, Heimfarth, and Pessoa-Pureur,
2008).
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In addition to p38 and ERK, TLR4 may also activate the JNK MAPK pathway.
This activation may result in the increased production and release of
proinflammatory MCP-1, IL-1β, and others (Liu, Gao, and Ji, 2012). Although the
receptor for MCP-1, CCR2, is not normally expressed on spinal neurons, it may be
expressed in DRG neurons following paclitaxel treatment (Zhang et al., 2013). This
change was not observed in the spinal cord in this model, although it did occur in the
spinal cord in a lumbar disc herniation model of neuropathy (Zhu et al., 2014). The
binding of cytokines and chemokines onto neuronal receptors may then sensitize
them to further stimuli. The proposed model therefore provides a twofold means by
which neurons in the spinal cord may be affected by astrocytes: first, by an increase
in synaptic neurotransmitter that may increase EPSPs and sensitize neurons, and
second, by further neuronal sensitization through cytokine and chemokine release.
To summarize the pathway that has been proposed, bortezomib first induces
damage within the peripheral nerve and DRG. HMGB1 from the DRG then signals
into the spinal cord and triggers a TLR4-mediated signal cascade that is potentiated
by binding to RAGE. MAPK pathways then alter the expression of several astrocytic
proteins. ERK decreases the expression of glutamate transporters, p38 increases
the expression of GFAP and Cx43, and JNK increases the expression of MCP-1 and
IL-1β. The changes in glutamate transporter and gap junction expression then
increase synaptic glutamate, which increases the likelihood of EPSPs in the neuron.
The parallel activity of cytokines and chemokines further sensitizes neurons,
increasing the likelihood of a response.
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There are several points along the proposed pathway in which alternative
signaling molecules may serve a similar role. Instead of the activity of HMGB1, it is
possible that MCP-1 or TNF-α may enter the spinal cord directly from the DRG. It is
also possible that excessive presynaptic activity in DRG neurons may trigger
downstream changes in the spinal cord, instead of the release of DAMPs or
cytokines. The proposed model is just one possibility that may explain the observed
phenomena in this dissertation, and further research is necessary to verify or
disprove this pathway.
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Figure 19. Proposed pathway for induction of BIPN model.
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6. APPENDIX: Early Expression of GFAP and OX-42
As a follow-up on observed changes in glial surface markers in bortezomibtreated animals (see chapter 3), it was deemed necessary to examine possible glial
activation at an earlier time point. One possibility of the lack of an observed change
in microglial activity was that there could be a transient activation of microglia that
returned to baseline activity by the 7-day time point that was observed. In order to
address this possibility, animals were treated with a single injection of 0.15mg/kg
bortezomib or an equivalent volume of saline and sacrificed 24 hours later for
immunohistochemistry (for full methods, see chapter 3).
The expression of GFAP and OX-42 at this time point did not differ
significantly between treatment groups (Fig. 20). GFAP expression was 97.1 ± 7.3%
of control, and OX-42 expression was 100.3 ± 7.1% of control. It is important to note
that, as previously mentioned, bortezomib has a half-life of 24 hours, and
proteasome activity does not return to basal levels until 72 to 96 hours following
bortezomib treatment. It is therefore unlikely that time points earlier than 24 hours

Fluorescence Intensity (Percent of Control)

would show any different effect.
Glial Marker Expression at 24 Hours
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Figure 20. GFAP and OX-42 expression at
24 hours following bortezomib treatment.
Animals treated with a single injection of
bortezomib (n=6) did not show significantly
different expression of GFAP or OX-42 24
hours later versus saline-treated controls
(n=6).
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